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Mixed Lineage Leukaemia 5 (MLL5) is a mammalian Trithorax group (TrxG) gene 
located at chromosome band 7q22, a frequently deleted region in myeloid 
malignancies. MLL5 was discovered and subsequently cloned in year 2002. Currently, 
there are a total of fifteen publications dedicated to MLL5.  
 
During the course of studying the restoration of p53 protein and reduction of Rb 
phosphorylation upon knockdown of MLL5, we found an intriguing link between the 
down-regulation of E6/E7 oncoproteins and MLL5 levels in HPV16/18-postive 
cervical cancer cell lines. We further characterized a novel MLL5 isoform (503 amino 
acids) which plays a role in activating E6/E7 through the association with the AP-1 
transcription factor in HPV-LCR. Moreover, knocking down MLL5β by using 
MLL5β-specific siRNA can down-regulate both E6 and E7 gene and protein 
expression, leading to the restoration of p53 and active phosphorylated Rb level. 
Furthermore, MLL5β can only be detected in HPV16/18-positive cell lines and 
primary human cervical carcinoma specimens.  
 
Seeing MLL5β can down-regulate both E6 and E7 in both HPV16 and HPV18-
positive cells, we are interested in the application of MLL5β-siRNA as a new 
therapeutic agent for HPV16/18-positive cervical cancer. We assessed the effect of 
MLL5β-siRNA on promoting cell death and suppressing growth of HPV16/18-
positive cells in both in vitro and in vivo experiments. Besides that, gamma irradiation 
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was combined with MLL5β-siRNA and the effectiveness of this combinatory 
treatment was compared with the current gold standard of cervical cancer treatment, 
the chemoradiotherapy using cisplatin drug. We found that MLL5β-siRNA treatment 
offered synergistic anti-cancer effects compared to E6 or E7-siRNA alone and 
MLL5β-siRNA can target both HPV16 and 18 subtypes, unlike E6 and E7-siRNAs 
which are subtype-specific. Moreover, MLL5β-siRNA has comparable anti-cancer 
effects as cisplatin but MLL5β-siRNA is more specific and hence reducing the 
adverse side-effects of cisplatin. Furthermore, we discovered that MLL5β might play 
a role in the cisplatin-mediated anti-cancer effects. The novel roles of MLL5 isoform 
in cervical cancer through E6/E7 regulations make it a potential therapeutic target and 
a biomarker for human cervical cancers.  
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1.1 Human cervical cancer  
Human cervical cancer is a malignant neoplasm in the human cervix, the narrow 
portion of the uterus that connects the lower part of uterus to the upper part of vagina. 
Two main forms of cervical cancers are squamous cell carcinoma, accounting for 
around 80 % of the cervical cancers, arise from the squamous cells in the epithelium 
of the cervix while around 15 % of the cervical cancers are adenocarcinoma, which 
arise from glandular tissue (zur Hausen, 1991; Walboomers et al, 1999; Cancer, 2007). 
Cervical cancers are the third most common cancer in the women worldwide and 
around 85 % of cervical cancers occur in developing countries (Ferlay et al, 2010). 
Prognosis for cervical cancers is generally poor especially in the later stage leading to 
a high mortality rate of cervical cancers in developing countries where screening is 
generally unavailable, inaccessible and unaffordable. This illustrates the importance 
of early detection in surviving against cervical cancers. 
 
In Singapore alone, cervical cancer is the seventh most common cancer among 
women between year 2003 to 2007 (Lim et al, 2012). Every year it has been estimated 
that around 184 women are diagnosed with cervical cancer and among them 71 
women will ultimately die of cervical cancer. Although the incidence rate and 
mortality rate of cervical cancer is relatively low compare to other countries in the 
same region, they are still higher compare to regions like North America and Europe. 
However cervical cancer in Singapore has been in a decreasing trend since year 1998, 
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which is an encouraging sign of the successful measures taken by the government to 
raise awareness of the importance of cervical cancer screening through program like 
CervicalScreen Singapore (Lim et al, 2012).    
 
Risk factors for cervical cancers includes chlamydia infection, stress, hormonal 
contraception and family history of cervical cancer but the most important risk factor 
is the infection of human papillomaviruses (HPV), which can be found in more than 
99 % of the cervical cancers (Bosch et al, 2002).  Hence, HPV infection has been 
recognized as the causative agent of cervical cancers. 
 
1.2 Human papillomavirus  
HPV is a non-enveloped, small double-stranded DNA virus that is strictly species-
specific and over 100 types of HPVs have been identified through using DNA 
sequencing. In general, HPV can be classified into two groups, the high-risk HPV and 
low-risk HPV. High-risk HPV including HPV16, 18, 31 and 45 are associated with 
cancers especially cervical cancers while low-risk HPV such as HPV6 and 11 are 
associated with benign genital warts (Golijow et al, 1999; Kehmeier et al, 2002; 
Schiffman & Castle, 2003; Bellanger et al, 2005). Besides that, there have been 
increasing evidences that suggest HPV infection is also related to other cancers such 
as anal, vulvar, vaginal and penile cancers (Parkin, 2006; Schiffman et al, 2007). 
Recently, HPV infection has also been found to associate with oral cancer, in 
particular oropharyngeal carcinomas (Jarboe et al, 2011; Bertolus et al, 2012; Rautava 
et al, 2012). 
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HPV infection is one of the most common sexually transmitted infections in the world 
and more than 80 % of sexually active adults were infected by HPV at some point of 
their lifetime (Dunne et al, 2007; Dunne et al, 2011). Most of the HPV infection are 
harmless and will be cleared by the immune system but in cases where a persistent 
infection of high-risk HPV occurred, this will dramatically increase the chance of 
developing cervical cancer (Hamid et al, 2009). Among the high-risk HPV, HPV 16 
and 18 are the most dangerous where they account for around 70 % of the HPV-
induced cervical cancers worldwide. The HPV genome encodes for six early genes 
(E1, E2 and E4 to E7), two late genes (L1 and L2) and a non-coding long control 
region (LCR) (Figure 1). Each of the HPV genes contributes to the survival and 
replication of the virus in which E1 and E2 have been found to be important in viral 
replication while E6 and E7 are found to be involved in host cell proliferation. L1 and 
L2 encode capsid proteins which are important for virus packaging. Besides that, E2 
has also been found to regulate virus replication through interaction with the LCR. 
Among the proteins expressed by HPV, E6 and E7 have been classified as oncogenes 







Figure 1. Genome map of HPV18. Various open reading frames (ORF) of viral 
proteins were indicated in arrows.  
 
1.3 E6 and E7 oncogenes 
For E6 and E7 to be expressed, the normally episomal HPV genome must become 
integrated into the host genome, and subsequently hijack the cellular replication 
mechanism for the expression of the various associated oncogenes (Kalantari et al, 
2001). In early phase of HPV infections where the virus still exist in an episomal state, 
viral E2 protein represses the expression of E6 and E7 proteins, along with its role as 
a replication factor. After persistent infection of HPV, whereby its DNA is 
successfully integrated into the host genome, E6 and E7 proteins are required to 
induce and maintain cellular transformation due to their abilities to interfere with 
apoptosis and cell-cycle regulation (Munger et al, 1989; Narisawa-Saito & Kiyono, 
2007). This is facilitated by the fact that the integration event often occurs within the 
E2 gene, leading to its disruption.  Disruption of the E2 gene in turn causes the loss of 
expression of the E2 protein, thereby lifting the repression effect on E6 and E7 
expressions. Moreover, transcription of both E6 and E7 are under the control of the 
same promoter (p97 for HPV16 and p105 for HPV18) and are translated from a 
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bicistronic mRNA (Schneider-Gadicke & Schwarz, 1986; Smotkin & Wettstein, 1986; 
Romanczuk et al, 1991). Hence, integration of the HPV genome allows the continual 
expression of both E6 and E7 (Figure 2). 
 
Figure 2. Integration of HPV genome into host DNA leads to loss of E2, lifting 
the E2 suppression on E6 and E7. Arrow denotes the site where E2 is truncated in 
the event of HPV integration. The suppressing effect of E2 on the LCR was lifted due 
to the lack of E2 upon integrating into the host genome, leading to the activation of 
E6 and E7 expression. 
 
 
E6 targets p53, a key tumour suppressor, through interaction with E6-associated 
protein (E6AP). p53 is critical in the prevention of neoplastic transformation through 
its activation of downstream genes such as p21 that promote genomic stability, cell 
cycle arrest, and apoptosis (Baker et al, 1989; Nigro et al, 1989; Geyer et al, 2000). 
E6AP is an endogenously expressed cellular protein which showed a high affinity for 
p53 when E6/E6AP complex was formed. The complex targets p53 for degradation 
through proteasome by its ubiquitin ligase function (Thomas et al, 1999). Hence, in 
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HPV-associated cervical cancer, p53 is fully functional but its level was decreased by 
E6 to a level that it no longer exerts its tumor suppressor functions. This is different 
from other pathogens-induced cancers where tumour suppressor activity was 
overcome by inducing mutation to the key tumour suppressors. Besides that, E6 also 
binds to histone acetyltransferases such as p300, CREB-binding protein (CBP) and 
ADA3, that further suppresses p53 functions (Patel et al, 1999; Zimmermann et al, 
1999; Zimmermann et al, 2000; Kumar et al, 2002). Moreover, increasing evidences 
suggest that E6 activates the expression of human telomerase reverse transcriptase 
(hTERT), thereby preventing the shortening of telomere and effectively immortalizing 
the host cells (Veldman et al, 2001; James et al, 2006; Liu et al, 2008; 
Katzenellenbogen et al, 2009). Furthermore, E6 oncoprotein was found to inhibit 
apoptosis through p53-independent pathway by inhibiting pro-apoptotic Bax protein 
(Magal et al, 2005; Vogt et al, 2006) and binding to tumour necrosis factor receptor 1 
(TNFR1) to impede TNFR1 apoptotic signalling (Duerksen-Hughes et al, 1999; 
Filippova et al, 2002). High-risk E6 also contains PSD95/Dlg/ZO-1 (PDZ) binding 
motif and is able to target cellular protein with PDZ domain for degradation, leading 
to cellular transformation through the loss of cell-cell interaction and polarity 
(Massimi et al, 2004; Massimi et al, 2008; Kranjec & Banks, 2011). Overall, an 
accumulation of E6 lifts the tumour suppressor activity by p53 which include the 
regulation of growth arrest and apoptosis after DNA damage along with p53-
independent apoptotic suppression, thereby promoting the progression of cancer 
development (Figure 3). 
 
On the other hand, E7 interacts mainly with cell cycle regulator protein 
retinoblastoma (pRb). In a normal cell cycle, pRb is in hypo-phosphorylated form and 
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as cell approaches S-phase, pRb is increasingly phosphorylated by cyclin 
D/CDK4/CDK6 complexes. Hypo-phosphorylated pRb binds to the transcription 
factor E2F and prevents its activation of downstream targets that leads to cell cycle 
progression (Dyson et al, 1989). When E7 binds to hypo-phosphorylated pRb, it 
prevents its interaction with E2F, thereby lifting the regulation on S-phase progression, 
effectively stopping the cell cycle regulation and drive the cell cycle to facilitate virus 
genome replication (Dyson, 1998). Besides that, E7 has been shown to degrade pRb 
through ubiquitin-proteasome mediated pathway (Boyer et al, 1996). Moreover, E7 
also binds to histone deacetylases which promotes E2F-dependent transcription as 
well as CDK2/cycline A and CDK2/cycline E which in turn phosphorylate pRb to 
induce S-phase progression (Arroyo et al, 1993; McIntyre et al, 1993; McIntyre et al, 
1996; Brehm et al, 1999). Furthermore, studies have shown that E7 binds to p21, and 
blocks p21-induced cell cycle arrest (Funk et al, 1997; Loignon & Drobetsky, 2002). 
In addition, E7 also bypasses host immune response and promote cell survival 
through the inactivation of interferon regulatory factor 1 (IRF-1) and the inhibition of 
interferon-α (IFN-α) (Barnard & McMillan, 1999; Perea et al, 2000). HPV16 E7 was 
also found to up-regulate interleukin-6 (IL-6) and Mcl-1 expressions to promote their 
anti-apoptotic property in lung cancer (Cheng et al, 2008b) as well as activates the 
cell survival B/Akt cell signalling pathway (Menges et al, 2006; Charette & McCance, 
2007). Overall, E7 promotes unchecked cell cycle progression and cell survival 
thereby promoting the proliferation of cancerous cells (Figure 4). 
 
The accumulation of E6 and E7 oncoproteins leads to the transformation of cellular 
phenotypes, which would most probably result in tumourgenesis. It has been shown 
that E6 and E7 together cause polyploidization soon after they are introduced into 
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cells, suggesting that E6/E7-mediated cellular transformation may lead to genomic 
instability, a hallmark of cancer development (Incassati et al, 2006). In addition, cell 
cycle arrest and checkpoints are de-regulated in these cells, due to the loss of tumour 
suppressor p53 and pRb family. Various studies have demonstrated that E6 and E7 are 
essential for the transformation and immortalization of human primary keratinocytes 
(Barbosa & Schlegel, 1989; Munger et al, 1989; Hudson et al, 1990; Sedman et al, 
1991). The expression of these two oncoproteins has been found to be under the 
control of the HPV long control region (LCR), located upstream of the E6 open 
reading frame. Despite extensive studies carried out to elucidate the regulatory 
property of LCR which involves a complex system of both viral and human 
transcription factors, a complete understanding of the mechanism is yet to be achieved 
(Nakshatri et al, 1990; Sibbet & Campo, 1990; Chong et al, 1991). Studies have 
shown that host cellular transcription factors such as activator protein 1 (AP-1) 
(Thierry et al, 1992; de Wilde et al, 2008) and specificity protein 1 (SP-1) (Gloss & 
Bernard, 1990; Hoppe-Seyler & Butz, 1992) are important in the positive control of 
E6/E7 expression in HPV. In particular, Thierry et al. (1992) have demonstrated the 
importance of two AP-1 sites in HPV18-LCR in the E6/E7 expressions. Other 
transcription factors including NF1(nuclear factor 1), YY1 (Yin Yang 1) and Oct-1 
have been found to play a role in the HPV E6/E7 expression through the LCR 




Figure 3. Effects of E6 on host cells. Multiple targets of E6 oncoprotein in host cells 
leading to malignant transformation. Upon E6 overexpression after integration of 
HPV into host genome, E6 along with E6AP leading to the loss of function of key 
tumor suppressor p53 (the most important and well studied target), lifting the cell 





Figure 4. Effects of E7 on host cells. Multiple targets of E7 oncoprotein in host cells 
leading to malignant transformation. The most studied target for E7 is the pRb, where 
E7 hyper-phosphorylates pRb, releasing the E2F transcription factor to promote S-
phase progression without proper control checkpoint. Overall, E7 promotes 
unchecked cell replication and cell survival. (Ganguly & Parihar, 2009) 
 
1.4 Current therapies for cervical cancer 
Conventional treatment of cervical cancer in advanced stage often employs a 
chemotherapy using platinum-based derivatives followed by radiotherapy; an 
important example of such chemotherapy drugs is cisplatin (Monyak et al, 1988; Rose 
et al, 1999). Studies have shown that through some yet to be identified mechanism, 
cisplatin has been found to repress E6 expression level in HeLa cells, leading to 
stabilisation of p53 protein and up-regulation of p53 downstream genes (Wesierska-
Gadek et al, 2002; Huang et al, 2004). Besides that, cisplatin was reported to enhance 
the radio-sensitivity in cervical cancer cell line through restoration of p53 functions 
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(Huang et al, 2004; Wang & Lippard, 2005). However, cisplatin functions primarily 
by targeting tumour cells that divide rapidly, therefore it lacks specificity and 
consequently also target normal cells, leading to unwanted side effects (Reedijk & 
Lohman, 1985; McAlpine & Johnstone, 1990; Fuertes et al, 2003). Besides that, two 
HPV vaccines have been approved by the United States Food and Drug 
Administration in 2006 that offers protection against HPV16 and 18 infections but do 
not possess any therapeutic effect against existing infection. 
 
Recently the use of RNA interference (RNAi) or small interfering RNA (siRNA) has 
emerged as a direct treatment for many types of cancers (Beh et al, 2009; Trembley et 
al, 2012). Hence, the precise targeting of specific genes by RNAi stands out as one of 
the most favourable cancer therapies in the near future. Many efforts have been made 
to explore the therapeutic potentials of direct suppression of E6 and E7 expression via 
siRNAs, since it is more specific in its action and their prominent role in the 
tumorigenesis of HPV-related cancers (Tan & Ting, 1995; Jiang & Milner, 2002; Butz 
et al, 2003; Hall & Alexander, 2003; Yoshinouchi et al, 2003). The E6 and E7 siRNA 
treatment has been shown to induce apoptosis and increased sensitivity to the effects 
of chemotherapy in HPV-positive cervical cancer cell lines in in vitro studies while 
tumors were found to be significant smaller in in vivo studies with immune-
suppressed mice (Tan & Ting, 1995; Jiang & Milner, 2002; Butz et al, 2003; Hall & 
Alexander, 2003; Yoshinouchi et al, 2003). Thus far, studies have shown the 





1.5 Mixed Lineage Leukemia (MLL) family proteins 
 
MLL family proteins are the homologue to Drosophila trithorax, which play a role in 
the repression of Homeobox (HOX) gene through modulating chromatin structure and 
histone modification during development. Currently there are five members in the 
MLL family, namely MLL1, MLL2, MLL3, MLL4/ALR and MLL5. MLL1 is the 
best studied protein in the family, with more than 40 fusion partners have been 
identified. The MLL proteins generally possess variable numbers of cysteine-rich 
Plant Homeodomain (PHD) zinc fingers and a Su(var)3-9, Enhancer-of-zeste and 
Trithorax (SET) domain at the C-terminal. A schematic diagram of all the five 
members in MLL family is illustrated in Figure 5. Emerging evidence has shown that 
PHD fingers are the binding or recognition modules for histone modification, whereas 
the SET domain possesses methyltransferase activity. In fact, except for MLL5, all 
other four proteins in the MLL family have been found to exert H3K4 (histone 4 
lysine 3) methyltransferase (HMT) activity and play a role as epigenetic regulator 
(Hughes et al, 2004; Yokoyama et al, 2004; Nightingale et al, 2007).  
 
The histone H3K4 methyltransferase activity of MLL1 has been found to regulate 
Hox gene expression and similarly, MLL2 forms a complex containing menin, WDR5 
and chromatin-remodeling components (Hughes et al, 2004; Yokoyama et al, 2004). 
On the other hand, MLL3 and MLL4/ALR are found in complexes containing ASC-2 
with H3 acetylation and H3 Lys-27 demethylation activities (Nightingale et al, 2007; 





Figure 5. Schematic diagram of MLL family protein members. Clusters of PHD 
finger and a single SET domain at the C-terminal can be observed in all members of 
MLL family except for MLL5, which only contains a single PHD finger and a SET 
domain at the N-terminal. The diagram is constructed base on the domain analysis 
results from SMART (http://smart.embl-heidelberg.de/). The evolutionary 
relationship among the family members is drawn using cladogram from ClustalW 




1.6 Mixed Lineage Leukemia 5 (MLL5) 
MLL5 gene was first discovered during the search for candidate myeloid leukaemia 
tumour suppressor genes from a commonly deleted 2.5 Mb segment within 
chromosome band 7q22, which is known to associate with myeloid malignancies 
(Fischer et al, 1997; Emerling et al, 2002). MLL5 is more distantly related to other 
MLL family members as it encodes only a single PHD domain instead of a cluster 
found in other members, with the SET domain located nearer to the N-terminal region 
of the protein. MLL5 also lacks DNA binding motifs of A-T hooks as well as the 
bromodomain that are commonly found in other MLL protein members (Emerling et 
al, 2002).  These may suggest that MLL5 does not bind directly to DNA but instead 
modulates transcription indirectly via protein-protein interactions through its PHD 
and SET domains.  
 
Even though the other MLL family members are known to involve in H3K4 activity, 
several reports suggested that MLL5 lacks such intrinsic methyltransferase activity 
(Nightingale et al, 2007; Madan et al, 2009). Nonetheless, Fujiki and his colleagues 
suggested that a short N-terminal isoform of MLL5 (608 amino acids) with both the 
PHD and SET domain possesses GlcNAcylation-dependent HKMT activity and 
facilitates retinoic acid-induced granulopoiesis (Fujiki et al, 2009). Furthermore, 
Sebastian et al (2009) demonstrated that even though MLL5 appears to be short of 
intrinsic histone methyltransferase activity, it is able to regulate the expression of 
histone modifying enzymes Lysine Specific Demethylase 1 (LSD1) and SET7/9 
through an indirect mechanism in quiescent myoblasts. Moreover, SET3, a S. 
cerivisiae protein with significant homology to the PHD and SET domain in the N-
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terminal of human MLL5 protein has been found to express histone deacetylase 
activity through forming complexes (Pijnappel et al, 2001; Sebastian et al, 2009). 
 
Three independent studies, reporting the genetic analysis of Mll5 deficiency in mice 
were published (Heuser et al, 2009; Madan et al, 2009; Zhang et al, 2009). These 
mice suffer from mild growth retardation but do not develop spontaneous leukemia. 
These studies which used different strategies to generate the Mll5 knockout mice 
highlighted the importance of Mll5 in hematopoietic stem cell fitness and 
spermatogenesis but is dispensable for embryonic development. Recent study also 
demonstrated the importance of MLL5 in spermatogenesis in Mll5 deficient male 
mice (Yap et al, 2011). However, a recent clinical study reported that higher MLL5 
expression levels were associated with better prognosis in acute myeloid leukemia 
(Damm et al, 2011). Our group has previously shown that over-expression or 
knockdown of MLL5 impeded cell cycle progression and proposed that MLL5 may 
participate in the cell cycle regulatory network at multiple stages of the cell cycle 
(Deng et al, 2004; Cheng et al, 2008a). Besides that, our group demonstrated that 
MLL5 is a substrate of Cdc2 kinase and phosphorylation of MLL5 is required for 
mitosis progression (Liu et al, 2010). Moreover, recent data in our group showed that 
MLL5 is a new cellular determinant of camptothecin (CPT) and has a regulatory 
function in p53 homeostasis (Cheng et al, 2011). In short, MLL5 has been found to be 
a multifunction protein which has been shown to play a role in cell cycle regulation, 





1.7 A novel isoform of MLL5 and its role in HPV16/18-associated cervical 
cancers: an overview 
This research project, focusing on a novel MLL5 isoform, was initiated during the 
course of studying the effects of MLL5 knockdown in various cell lines from my 
group member, Dr Cheng Fei. We observed a marked accumulation of p53 in HPV18-
positive cervical cancer cell line HeLa upon MLL5 knockdown. On the other hand, 
HPV-negative cell lines did not show p53 accumulation. Hence, I carried on to 
investigate this observation and interestingly, I found out that my hypothesis that 
HPV oncoproteins E6 and E7 are involved were soon proved to be true. Subsequently, 
from validation experiments, I further identified and characterized a novel MLL5 
isoform that we named MLL5β as the activator of E6 and E7 expressions in 
HPV16/18-positive human cervical cancer cell lines. MLL5β in human primary 
cervical carcinoma specimens were also studied and with the help of other group 
members, we published our work of MLL5β in 2011 (Yew et al, 2011), which I will 
elaborate in Section 3. Next, we filed a patent on our discovery of MLL5β and we 
assessed the potential of MLL5β as a biomarker and therapeutic target for HPV-
related human cervical cancer, which I will discuss in Section 4. Currently, the project 
is still on going and we are publishing a second manuscript focusing on the potential 





2. Materials and methods 
 
2.1 Cell lines and reagents 
Human cervical carcinoma SiHa, HeLa and C33A, embryonic kidney cells HEK 
293T, colorectal carcinoma HCT116, osteosacoma U2OS, human diploid fibroblasts 
WI-38, human promyelocytic leukemia cells HL60 and human erythromyeloblastoid 
leukemia cells K562 were cultured as monolayer in Dulbecco’s Modified Eagles 
Medium (DMEM, Gibco). Human cervical carcinoma Caski, human pre-B leukemic 
cells REH and human leukemic monocyte lymphoma cells U937 were cultured in 
Roswell Park Memorial Institute 1640 (RPMI, Gibco). All cell lines were purchased 
from American Type Culture Collection (ATCC). The respective mediums were 
supplemented with 10% fetal bovine serum (FBS, Hyclone), 2 mM glutamine (Gibco) 
and 100 units/ml penicillin/streptomycin (Gibco) at 37 ºC with 5 % CO2. This 
medium is referred as complete medium in subsequent experiment. The cells were 
routinely passaged at 1:6 ratios (v/v) thrice weekly with the use of 1.0 ml of 0.25 % 
Trypsin-Ethylene-Diamine Tetracetic acid (EDTA) (Gibco). For WI-38 fibroblast, 
cells with less than 10 passages were used for the experiments. 
 
2.2 RNA interference and delivery 
BLOCK iTTM RNAi designer software (Invitrogen, Carlsbad, CA, USA) were used to 
identify potential siRNA targeting sites within human MLL5 mRNA sequence. Four 
different MLL5-siRNA duplexes (#1, #2, #3 and #4) targeting nucleotide positions at 
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1063, 1147, 5215 and 6807 respectively, from the transcription starting point 
[National Centre for Biotechnology Information (NCBI) reference sequence: 
NM_182931.2]. MLL5β-specific siRNA was designed to target MLL5β specifically 
but not MLL5. HPV16 and HPV18 E7 siRNAs were designed to target each HPV 
subtype specifically. Scrambled-siRNA was used as a control. All the siRNA 
duplexes were synthesized by 1st BASE (Singapore) and the sequences are 
summarized in Table 1. The siRNAs used are dissolved in DEPC-water at a 
concentration of 20 μM before further dilution into working concentration following 
Table 2. 
 
Cells were seeded one day before to achieve cell confluency of 40-60 % on the day of 
transfection. In performing siRNA transfection, cells were cultured in complete media. 
Transfection mixtures consist of Lipofectamine RNAiMAX (Invitrogen) and siRNA 
were diluted with serum-free DMEM. The specific quantities of the reagent and 
siRNA added in preparation of the transfection mixes for the different cell culture 
vessels are summarised in Table 2. The diluted siRNA and Lipofectamine RNAiMAX 
were prepared in different tubes and then combined before the transfection mix was 
incubated at room temperature (RT) for approximately 20 min to allow for the 
formation of siRNA duplex-Lipofectamine RNAiMAX complexes. The transfection 
mix was then added drop-wise into the cell culture vessels. The cell media was 
subsequently changed 24 h post-transfection. Cells were cultured for 72 h post-





Table 1: Nucleotide sequences of the siRNA used for MLL5 or MLL5β gene 
silencing 
 
siRNA ID  siRNA sequences (5’-3’) 
SC (Scrambled) Sense UUCUCCGAACGUGUCACGUdTdT 
Antisense ACGUCACACGUUCGGAGAAdTdT 
MLL5 #1 (1063) Sense CGCCGGAAAAGGGAAAAUAdTdT 
Antisense UAUUUUCCCUUUUCCGGCGdTdT 
MLL5 #2 (1147) Sense GCAUUUCAGCAUACUCCAAdTdT 
Antisense UUGGAGUAUGCUGAAAUGCdTdT 
MLL5 #3 (5215) Sense CAGCCCUCUGCAAACUUUCAGAAUUdTdT 
Antisense AAUUCUGAAAGUUUGCAGAGGGCUGdTdT 
MLL5 #4 (6807) Sense GCACUGGUUGGGCAUUUUAdTdT 
Antisense UAAAAUGCCCAACCAGUGCdTdT 
MLL5β Sense GACUAGUCUCGCGUAUAUUdTdT 
Antisense AAUAUACGCGAGACUAGUCdTdT 
HPV16 E6 Sense GAGGUAUAUGACUUUGCUUdTdT 
Antisense AAGCAAAGUCAUAUACCUCdTdT 
HPV16 E7 Sense AGGAGGAUGAAAUAGAUGGdTdT 
Antisense CCAUCUAUUUCAUCCUCCUdTdT 
HPV18 E6 Sense CACUUCACUGCAAGACAUAdTdT 
Antisense UAUGUCUUGCAGUGAAGUGdTdT 






Table 2: Optimised volumes, concentrations of Lipofectamine RNAiMAX and 



























12 in100 1.6 in 100 1.0 12 
6-well plate 24 in 200 3.2 in 200 2.0 12 
60 mm 
plate 
64 in 500 8.5 in 500 5.0 12 
 
 
2.3 Construction of plasmids  
FLAG-tagged MLL5 and FLAG-tagged MLL5 C-terminal expression vector (amino 
acid 1113 to 1858) were previously constructed in pEF6/V5-His-vector (Invitrogen) 
in frame with BamHI and XbaI sites (Liu et. al., 2010). GFP-tagged MLL5 (GFP-
MLL5-FL) and GFP-tagged MLL5 C-terminal expression vector (GFP-CT) was 
generated by cloning the appropriate MLL5 region into pEGFP-C1 vector (Clontech) 
in frame with SalI and BamHI sites. MLL5β cDNA sequence was amplified from 
HeLa cDNA by polymerase chain reaction and the PCR amplicons were digested with 
BamHI and NotI sites and cloned into pEF6/V5-His vector (Invitrogen) for FLAG-
tagged MLL5β expression vector (FLAG-MLL5β); while digested with SalI and 
BamHI sites and cloned into pEGFP-C1 vector (Clontech) for GFP-tagged MLL5β 
expression vector (GFP-MLL5β). Primers used for cloning were listed in Table 3. 
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To generate constructs for luciferase assay for the HPV18 (NCBI Reference Sequence: 
AY262282.1) LCR promoter activity, a 958 bp (nucleotides 7018 to 119) fragment 
containing the LCR and p-105 promoter was cloned into pGL3-basic vector (Promega) 
through XhoI and HindIII sites. The plasmid generated, pGL3-HPV18FL (full length), 
has the HPV sequence solely responsible for the luciferase gene expression. Deletion 
constructs were generated in similar manner by using appropriately designed primers 
to create HPV18 LCR of decreasing size.  The exact fragment of HPV18 LCR cloned 
into the pGL3-basic vector was indicated by the number on the primer itself. As an 
example, pGL3-HPV18A has the fragment from 7018 bp to 119 bp of the HPV18 
sequence. 
 
GFP-MLL5β* (sequences in Table 3) was constructed by mutating the targeting site 
of the MLL5β-siRNA#1 so that the GFP-MLL5β expressed by this mutant is not 
knocked down by the siRNA while SET mutant contains an inactivated SET domain 
at amino acid 358 where tyrosine was mutated to alanine (Y358A). In AP-1 mutant 
construct, the AP-1 transcription factor binding site at 7326 bp was mutated while in 
SP-1 mutant construct, the SP-1 transcription factor binding site at 7314 bp was 
mutated. The mutant constructs were generated using the Quick Change site-directed 
mutagenesis kit (Stratagene). Two complementary oligonucleotides containing the 
desired mutation were synthesized and the PCR reaction was prepared by adding 5 μl 
of 10 X reaction buffer, 50 ng of template plasmid, 125 ng of forward and reverse 
primers, 1μl of dNTP mix (10 mM), 1 μl of Pfu DNA polymerase (2.5 U/μl) 
(Stratagene, 600250) and variable amount of water to a final volume of 50 μl. The 
PCR reaction was run using the following parameters: 30 sec at 95 °C for 1 cycle, 30 
34 
 
sec at 95 °C, 1 min at 55 °C and 2 min/kb of plasmid length at 68 °C for 18 cycles. 
Following the PCR reaction, the parental plasmid was digested by adding 1 μl of the 
Dpn I restriction enzyme (20 U/μl) (New England BioLabs, R0176) and incubated at 
37 °C for 2 h. 5 μl of the Dpn I treated DNA was transformed into competent DH5α, 
and colonies were amplified and plasmids containing the desired mutation were 
confirmed by DNA sequencing. 
 
Similarly, for HPV16 (NCBI Reference Sequence: NC_001526.2), luciferase 
constructs were generated through XhoI and HindIII sites into pGL3-basic vector 




Table 3: Primers used for cloning and their sequences 
Primers used for the cloning of MLL5β 











Primers used for the cloning of HPV18 luciferase constructs 











































































Restriction enzyme sites were underlined. 
 
2.4 Calcium-phosphate mediated DNA plasmid transfection 
Cells were seeded on 60 mm plate to achieve approximately 50 % cell confluency on 
the day of transfection. The transfection mixture for a typical 60 mm dish is listed in 
Table 4. To a 1.5 ml eppendorf tube, DNA was added to the middle part of the water 
while CaCl2 was added to the bottom part of the water. This DNA-CaCl2 mixture was 
mixed gently and thoroughly before transferred drop-wise to another 1.5 ml eppendorf 
tube containing 2X HBS solution (280 mM NaCl, 10 mM KCl, 1.5 mM Na2HPO4, 
12 mM Glucose, 50 mM HEPES, pH7.05). This DNA-CaCl2–HBS mixture was 
mixed gently with the pipette till the solution is homogenous and this transfection 
mixture was incubated at RT for 30 min before adding drop-wise slowly into the cell 
culture vessel. After 8 hr, fresh medium was given to the cells. Transfected cells were 
ready for downstream applications after 48 hr of transfection. Different amount of 
DNA plasmid was optimized for different cell lines as shown in Table 4. Transfection 






Table 4: Transfection mixture using calcium-phosphate method for a typical 60 
mm dish 
 
60 mm dish 
 
Components Volume for 293T (µl) Volume for HeLa/SiHa 
(µl) 
DNA Variable (3 to 6 µg DNA in 
maximum volume of 180 
µl )  
36 µg (in maximum 
volume of 180 µl) 
2.5M Calcium chloride 
solution 
20 20 
Water Variable Variable 
Total 200 200 
Add the DNA-calcium chloride mixture drop-wise into 2X HBS solution 
















24 well plate 
Components Volume for 293T (µl) Volume for HeLa/SiHa 
(µl) 
DNA Variable (300 to 600 ng 
DNA in maximum volume 
of 22.5 µl )  
4.5 µg (in maximum 
volume of 22.5 µl) 
2.5 M Calcium chloride 
solution 
2.5 2.5 
Water Variable Variable 
Total 25 25 
Add the DNA-calcium chloride mixture drop-wise into 2X HBS solution 





2.5 Total cell extract preparation  
For total cell extract preparation, cells were collected by trypsinization, washed twice 
with ice-cold PBS, and directly lysed in Laemmli sample buffer (62.5 mM Tris-HCl 
pH 6.8, 2.5% SDS, 10% glycerol, 0.01% bromophenol blue) with dithiothreitol (DTT, 
100 mM) in a concentration of 2 x 107 cells/ml. The lysate was boiled at 100 °C for 3 
min and sonicated for 20 sec at 20% output power (Sonics VCX130, Newtown, CT, 





2.6 Cell lysate preparation using mild lysis buffer  
Cells were harvested by trypsinization, washed twice with ice-cold PBS, and 
resuspended in mild lysis buffer supplemented with protease and phosphatase 
inhibitors [150 mM NaCl, 20 mM, Tris-HCl (pH 8.0), 1% Triton X-100, 2 mM 
phenylmethylsulfonyl fluoride, 2 μg/ml leupeptin, 2 μg/ml aprotinin, 1 μg/ml 
pepstatin A, 1 mM Na3VO4, and 5 mM NaF] in a concentration of 4x107 cells/ml. The 
cell lysate was passed through a syringe attached with 21G needle for 10 times to 
shear the genomic DNA. The lysate was incubated on ice for 15 minutes before 
centrifugation at 13000 rpm for 15 minutes at 4 ⁰C. The supernatant was transferred 
to a new tube and frozen at -80 ⁰C. 
 
2.7 Immunoprecipitation and Western blotting  
293T cells were first transfected with peGFP-MLL5β and pGL3-HPV18FL according 
to Section 2.4. For double transfection, each individual plasmid was added in the 
same amount but with higher concentration so that the final volume of the transfection 
mix was not changed. After 8 hr of the first transfection, cell culture media was 
changed before a second transfection of peF6-FLAG-c-Jun was performed as 
described in Section 2.4. Cells were incubated for 48 hr after second transfection 
before lysed in mild lysis buffer into 10 million cells in 1 ml of lysate. For every 500 
μl of lysate, pre-clearing was performed by rotating with 10 μl of protein A/G-agarose 




For each IP reaction, 500 μl of pre-cleared lysate was incubated with 2 μg of anti-
FLAG (Sigma-Aldrich, F3165) at 4 °C for 2.5 h, followed by 1.5 h incubation with 10 
μl of protein A/G-agarose beads (eBioscience  #00-8811) at 4 °C with constant end-
to-end rotation. The immune complexes were washed three times with mild lysis 
buffer. Proteins bound to the beads were then eluted with 60 μl of LSB/DTT (4:1 ratio) 
and boiled at 100 ⁰C for 3 min. The beads were then centrifuged at 5000 x g for 1 min 
to dissociate the bound proteins. The supernatant was transferred to a new tube and 
kept at -20 ⁰C for further Western blotting analysis. Conditions for Western blotting 
are listed in Table 5 and Table 6 while list of antibodies used are listed in Table 7. 
SDS-PAGE was run at constant 100 V until the dye front just exited the gel 
(approximately 90 to 105 min) and transfer was done at constant 70 mA for 2 hr.  
 




(protein < 150 
Transfer Buffer 
(protein ≥ 150 TBS 
100 mM Tris base 
0.384 M glycine 
0.1 % SDS 
25 mM Tris base 
150 mM glycine 
20 % (v/v) methanol 
25 mM Tris base 
150 mM glycine 
20 % (v/v) 
methanol 
0.05 % SDS 
10 mM Tris-HCl, 
150 mM NaCl, 
2.5 mM KCl 

















5 % skim 
milk in TBS 




RT for 2 hr 
5 % skim milk 
in TBS for 
overnight in 4 
⁰C 
5 % skim milk 
in TBS for 2 hr 
at RT 
TBS/0.05 % Triton 
X-100 for 1 hr with 
change of buffer in 
every 5 min 
FLAG M2 
antibody 
5% milk  
in TBS for 2 
hr in RT 
5% milk in 
TBS for 
overnight in 4 
⁰C  
5% milk in 
TBS for 2 hr at 
RT 
TBS/0.05% 
Tween-20 for 30 
min with change of 





milk in TBS 
for 2 hr in RT 
5% skim milk 
in TBS for 
overnight in 4 
⁰C 
5% skim milk 
in TBS for 2 hr 
at RT 
TBS/0.05% 
Tween-20 for 30 
min with change of 




















Manufacturer Catalogue  No. 
Dilution Factor 
for Western blot 
MLL5-1157 Self-raised Targets MLL5 central 1:5000 
MLL5-227 Self-raised Targets MLL5 N-terminus 1:5000 
Actin Santa Cruz SC-1616 1:250 
HPV16/18-E6 Santa Cruz SC-460 1:100 
HPV18-E7 Santa Cruz SC-1590 1:100 
p53 Santa Cruz SC-126 1:500 
pRB Santa Cruz SC-126 1:250 
p21 Cell Signalling #2946 1:500 
Cleaved-
PARP 
Cell Signalling #9541 1:2000 














Santa Cruz sc-2384 1:10000 
Mouse IgG  
Mouse beads 
(50% slurry) 
eBioscience #00-8811 N.A. 
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2.8 RNA extraction and semi-quantitative real-time PCR (qPCR) 
Total RNA was extracted using TRIzol reagent (Invitrogen #15596) and the cDNA 
was synthesized using iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). 
About 2 million cells were collected by trypsinization, followed by centrifugation at 
200 x g for 3 min at 4°C. Cell pellet was homogenized in 1 ml TRIzol reagent for 5 
min at room temperature. Chloroform (200 µl) was added to the homogenized sample 
and mixed vigorously for 15 sec. After incubation for 5 min at RT and centrifugation 
at 13 000 rpm for 15 min at 4°C, the upper aqueous phase (450 µl) was transferred to 
a new RNase-free eppendorf tube. RNA was precipitated by addition of 0.5 ml 
isopropanol and collected by centrifugation at 13 000 rpm for 10 min at 4°C. The 
RNA pellet was washed with 75 % ethanol (prepared using absolute ethanol and 
nuclease-free water), briefly air-dried, and dissolved in nuclease-free H2O (variable 
amount). The RNA concentration was determined by measurement of absorbance at 
260 nm using NanoDrop 2000c. 
 
For semi-quantitative real time PCR (qPCR), KAPA SYBR FAST One-step qPCR 
Master mix (KK4670) was used. The various gene expression levels were measured 
using the iQ5 qPCR machine (Biorad). For each reaction, 75 ng of total RNA, 1 μl of 
forward and reverse primer each (10 μM), 1 μl KAPA Reverse Transcriptase Mix and 
nuclease-free H2O (variable amount) were mixed with 25 μl of the KAPA SYBR 
FAST qPCR Master Mix and resuspended well to get 50 μl of 1x reaction mix. The 
reaction mix was aliquoted into 3 tubes and incubated in the iQ5 machine as follows: 
cDNA synthesis at 50 ⁰C for 10 min, reverse transcriptase inactivation at 95 ⁰C for 5 
min, PCR cycling and detection for 45 cycles (10 sec at 95 ⁰C, 20 sec at 60 ⁰C) and 
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melt curve analysis [1 min at 95 ⁰C, 1 min at 55 ⁰C and 10 sec at 55 ⁰C (80 cycles, 
increasing each by 0.5 ⁰C each cycle)]. GAPDH was used as an internal control. The 
sequences of primers used in the quantitative PCR were listed in Table 8. 
Table 8: Primers used in qPCR  
 
Primers  Sequence (5’-3’) 
MLL5 Forward CCACCACAAAAGAAAAAGGTTTCTC 
Reverse GTGTTGGTAAAGGTAGGCTAGC  
MLL5β Forward GAAAACCCAGAGTGCCCTGTTCTA 
Reverse CAATATACGCGAGACTAGTCTT 
GAPDH  Forward GTGAAGGTCGGAGTCAACG 
Reverse TGAGGTCAATGAAGGGGTC 
HPV16E6 Forward CTGCAATGTTTCAGGACCCA 
Reverse TCATGTATAGTTGTTTGCAGCTCTGT 
HPV16E7 Forward AAGTGTGACTCTACGCTTCGGTT 
Reverse GCCCATTAACAGGTCTTCCAAA 
HPV18E6 Forward GTGCCAGAAACCGTTGAATCC 
Reverse CGACGCCAGCTATGTTGTGAAATCGTCG 




2.9 Tissue specimens 
A total of eight human cervical carcinoma tissue specimens (6 squamous cell 
carcinomas; 2 adenocarcinomas) were analyzed. All primary tumor specimens were 
pre-treated biopsies from women with cervical carcinoma of cervix treated in 
Singapore General Hospital between December 2010 to February 2011. The samples 
were obtained by Associate Professor Tay Sun Kuie. All patients were informed and 
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agreed to the use of their biological sample for scientific research in accordance with 
Singapore regulations. The tissues were excised into equal parts for both RNA and 
genomic DNA extraction. Total RNA was extracted from the samples by using 
TRIzol (Section 2.8) and cDNA was generated from total RNA using MLL5β-specific 
primer (MLL5β.reverse, Table 3). Genomic DNA was extracted by using Wizard 
Genomic DNA Purification Kit (Promega A1120). The tissue was minced to small 
pieces using forceps and 600 μl of chilled Nuclei Lysis Solution was added to the 
tissue before incubation at 65 °C for 30 min.  200 μl of Protein Precipitation Solution 
was then added and vigorously vortex for 20 sec and then chilled on ice for 5 min 
before centrifugation at 13000 x g for 4 min to pellet down the protein in a tight white 
pellet. The supernatant was removed carefully and added into 600 μl of RT 
isopropanol and mixed by inversion until white thread-like strands of DNA formed. 
The DNA was centrifuged at 13000 x g for 1 min and the supernatant was removed 
before the pellet was washed with 70 % ethanol. The DNA was centrifuged again at 
13000 x g for 1 min and supernatant was removed to allow the DNA pellet to be air 
dried. 100 μl of Rehydration Solution was then added to the pellet and incubated at 
RT overnight. Genomic DNA was stored in 4 °C for further downstream applications. 
 
HPV genotyping was performed by using the genomic DNA (0.5 μg) as template in 
PCR. DNA was amplified by PCR by Taq polymerase (Roche, #11578553001) with 
primers (GP5+ and GP6+, MY09 and MY11) specific for fragments of the HPV 
(Zehbe & Wilander, 1996). The PCR reaction was set up as follows: 5 µl PCR buffer, 
6 µl 25 mM MgCl2, 1 µl dNTP mix, 1 µl forward primer (final concentration: 0.5 µM), 
1 µl reverse primer (final concentration: 0.5 µM), 0.5 µl Taq DNA polymerase and 
47 
 
nuclease free water (top up to 50 µl). The thermal cycler was set up as follows: 94 °C 
3 min, 40 cycles of 3-step cycling (1 min denaturation at 94 °C, 2 min annealing at 
56 °C, and 2 min extension at 72 °C), followed by final extension at 72 °C for 7 min. 
Primers PC04 and GH20 that are specific to β-globin were used as loading control to 
exclude false-negative results. Amplicons from GP5+/GP6+ and MY09/MY11 were 
extracted from gel and sent for sequence to determine the HPV subtype. Primers used 
were listed in Table 9 below. 
Table 9: Primers used for HPV genotyping 







M=A/C, R=A/G, W=A/T, Y=C/T 
 
2.10 Chromatin Immunoprecipitation (ChIP) 
FLAG-MLL5β or FLAG-CT was transfected into HeLa cells for 48 hr before cells 
were being harvested for ChIP. For each sample, 50 million transfected HeLa cells 
were cross-linked by adding formaldehyde (Sigma-Aldrich #252549) into the culture 
media at a final concentration of 1 % for 10 min at room temperature. The 
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formaldehyde was then quenched by glycine (final concentration: 125 mM) at RT for 
5 min. Cells were rinsed with PBS for three times, scraped off and collected in a 15 
ml Falcon tube by centrifugation at 700 x g for 5 min at 4 °C. Cell pellet was then 
resuspended in 5 ml buffer 1 (50 mM HEPES-KOH pH 7.5, 140 mM NaCl, 1mM 
EDTA, 10 % glycerol, 0.5 % NP-40, 0.25 % Triton X-100, supplemented by protease 
and phosphatase inhibitors) and mixed using a rotator (60 rpm) for 10 min at 4 °C. 
Cell suspension was then centrifuged at 1350 x g for 5 min at 4 °C, and the pellet was 
resuspended in 5 ml buffer 2 (10 mM Tris-HCl pH 8.0, 200 mM NaCl, 1 mM EDTA, 
0.5 mM EGTA, supplemented with protease and phosphatase inhibitors) followed by 
rotating-mixing (60 rpm, 10 min, 4 °C ). The suspension was again centrifuged at 
1350 x g for 5 min at 4 °C; the pellet was resuspended 3.5 ml buffer 3 (10 mM Tris-
HCl pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1 % Na-Deoxycholate, 
0.5 % N-lauroylsarcosine, supplemented by protease and phosphatase inhibitors) and 
sonicated at 40 % amplitude for 15 minutes, consisting of 15 cycles of 30 seconds 
sonication with 30 seconds cool down interval to generate DNA fragments of around 
300-500 bp. The sonicated lysate was mixed with 350 µl 10% Triton X-100, 
centrifuged at 20000 x g for 10 min at 4 °C and the supernantant was incubated with 2 
µg mouse IgG (sc-2025, Santa Cruz) or FLAG antibody (F3165, Sigma-Aldrich) at 
4 °C with constant rotation (60 rpm) for overnight. The lysate-antibody complexes 
were then incubated with anti-mouse IP beads (30 µl slurry, eBioscience, CA, USA) 
for 2 hr. The immune complexes were washed with 1 ml buffer 4 (50 mM HEPES-
KOH pH 7.5, 500 mM LiCl, 1 mM EDTA, 1.0 % NP-40, 0.7% Na-Deoxycholate) for 
3 times, followed by washing with 1 ml buffer 5 (10 mM Tris-HCl pH 8.0, 1 mM 
EDTA, 50 mM NaCl) for once, and eluted by incubating the complexes with 250 µl 
elution buffer (50 mM Tris-HCl pH8.0, 10 mM EDTA, 1 % SDS) for 15 min. The 
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eluates were then collected by centrifugation at 16000 x g for 1 min at room 
temperature. The eluates were reverse-crosslinked by incubation at 65 °C for 
overnight, mixed with 250 µl of buffer TE, and treated with RNase A (final 
concentration: 0.2 mg/ml, QIAGEN, #19101) at 37 °C  for 2 hr. The proteins in the 
immune complexes were removed by incubation with proteinase K (final 
concentration: 0.2 µg/ml, QIAGEN, #19131) at 55 °C for 2 hr. To purify the DNA, 
phenol:chloroform:isoamyl alcohol (500 µl, pH 8.0, Sigma-Aldrich, P2069) was 
added to the RNase A- and proteinase K-treated sample. After centrifugation at 10000 
x g for 10 min at 4 °C, the aqueous phase (200 µl) was transferred to a new tube and 
mixed with equal volume of isopropanol. The mixture was chilled for 1 hr at -20 °C 
and centrifuged at 4 °C for 15 min at 21000 x g. The pellet was then washed with 70 % 
ethanol once, briefly air-dried and solubilized in 20 µl nuclease-free water.  
 
DNA was amplified by PCR by Taq polymerase (Roche, #11578553001) with 
primers specific for fragments of the HPV18 LCR. The PCR reaction was set up as 
follows: 5 µl PCR buffer, 4 µl 25 mM MgCl2, 1 µl dNTP mix, 1 µl forward primer 
(final concentration: 0.5 µM), 1 µl reverse primer (final concentration: 0.5 µM), 0.5 
µl Taq DNA polymerase and nuclease free water (top up to 50 µl). The thermal cycler 
was set up as follows: 95 °C 15 min, 30 cycles of 3-step cycling (0.5 min denaturation 
at 94 °C, 0.5 min annealing at 56 °C, and 1 min extension at 72 °C), followed by final 





Table 10: Primers used for ChIP 









2.11 Rapid amplification of cDNA ends  
Putative MLL5 isoform was cloned using SMARTer RACE cDNA Amplification kit 
(Clontech #634923) using the protocols, oligonucleotides and reagents provided in the 
kit. PolyA+ mRNA was extracted from cells using Oligotex Direct mRNA Mini Kit 
(QIAGEN #70022) and used as template for both 5’ and 3’-RACE experiments. Total 
RNA was extracted from cells using TRIzol as described in section 2.8. RNase-free 
water was added to 200 µg of total RNA to make up to 250 µl. 250 µl of Buffer OBB 
and 15 µl of Oligotex suspension pre-warmed to 37 °C were added to the RNA and 
mixed thoroughly by pipetting. The mixture was then incubated for 3 min at 70 °C 
before further incubation of 10 min at RT. Oligotex:mRNA complex was pelleted 
down by centrifugation at 18000 x g for 2 min and the supernatant was removed 
carefully. After which the pellet containing Oligotex:mRNA complex was 
resuspended in 400 µl Buffer OW2 and transferred into a small spin column provided 
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before subjected to centrifugation at 18000 x g for 1 min. Repeat the wash by Buffer 
OW2 for another time and add 50 ul of Buffer OEB, pre-heated to 70 °C onto the 
column and pipet up and down to resuspend the resin before centrifuged at 18000 x g 
for 1 min to collect the mRNA. The collection step was repeated once to maximise the 
yield.  
 
To generate 5’- and 3’-RACE-Ready cDNA using the SMARTer RACE cDNA 
Amplification Kit, for each reaction, 4 µl of Buffer Mix consist of 2 µl of 5X First-
Strand Buffer, 1 µl of DTT (20 mM) and 1 µl of dNTP Mix (10 mM) was prepared 
and mix well before setting aside at RT. The rest of the recipe for the 5’- and 3’-
RACE-Ready cDNA was listed in Table 11 below. 
Table 11: Recipe for 5’- and 3’-RACE-Ready cDNA 
 5’-RACE-Ready-cDNA 3’-RACE-Ready-cDNA 
poly A+ RNA 200 ng in 1 µl to 2.75 µl 200 ng in 1 µl to 3.75 µl 
5’-CDS Primer A 1 µl 0 
3’-CDS Primer A 0 1 µl 
Sterile water Final volume of 3.75 µl Final volume of 4.75 µl 
 
 
The reagents in Table 11 was mixed and incubated at 72 °C for 3 min, followed by 42 
°C for 2 min before 1 µl of SMARTer IIA oligo was added to the 5’-RACE cDNA 
synthesis reaction. After that, 0.25 µl of RNase inhibitor (40 U/µl) and 1 µl of 
SMARTScribe Reverse Transcriptase (100U) were added to the 4 µl Buffer Mix 
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prepared previously to a total volume of 5.25 µl of Master Mix. The 5.25 µl Master 
Mix was then added to the 4.75 µl of the reagent mixture in Table 11 for a total 
volume of 10 µl. The contents were mixed by gentle pipetting before incubated at 42 
°C for 90 min followed by 70 °C for 10 min. Add 250 µl of Tricine-EDTA Buffer to 
dilute the final product. 
 
Using 5’- and 3’-RACE-Ready-cDNA, PCR was carried out to amplify the 5’ and 3’ 
end of the putative MLL5β mRNA as described in the PCR step in Section 2.9. The 
gene-specific primers used for both 5’and 3’-RACE recognized exon 7 of MLL5 and 
are as follow: 5primeM5.rev (5’- TTTCCCTTTTCCGGCGTTGT) and 3primeM5.for 
(5’- CAACGCCGGAAAAGGGAAAAT). RACE products were cloned into pCR2.1-
TOPO (Invitrogen, USA) using chemically competent DH5α cells in accordance to 
the protocol. In brief, 4 μl of fresh PCR products were incubated with 1 μl Salt 
Solution (1.2 M NaCl and 0.06 M MgCl2) and 1 μl of TOPO vector to a total of 6 μl. 
The mixture was incubated for 20 min at RT before 5 μl was added into the competent 
cells for 30 min followed by heat shock at 42 °C for 45 sec. Competent cells were 
centrifuged and the bacteria pellet was plated on a LB agar plate with ampicillin. The 
colonies formed were subjected to restriction enzyme screening using EcoRI enzymes 
and successful clones were sent for DNA sequencing (1st BASE, Singapore) using 






2.12 Dual luciferase assay 
A dual-luciferase reporter assay (Promega E1910) was employed to measure the 
transcription activity of the promoter region in interest. Cells cultured in 24-well 
plates were transfected with calcium phosphate method as described in Section 2.4 
along with pRL-TK in a 1/10 ratio (450 ng) with respect to the pGL3 vector (4.5 μg) 
as internal control. For 293T cells which does not express MLL5β endogenously, 
GFP-MLL5β was introduced exogenously together with pGL3 vectors in a double 
transfection where amount of each DNA used was kept unchanged (400 μg) by 
increasing the concentration of the DNA solution so as to keep the final volume of the 
transfection mix unchanged. 
 
Cells were then harvested 48 hr post-transfection and each sample was read in 
triplicates by using a luminometer (Tecan Ultra 384) following the protocol provided. 
Briefly, Passive Lysis Buffer 5X was diluted to 1X by distilled water. For each well in 
24well plate, 100 μl of 1X Passive Lysis Buffer was added after washing one time by 
PBS. The plate was then subjected to gentle shaking at RT for 15 min. While waiting 
for the plate, Luciferase Assay Reagent II (LAR II) was prepared by resuspending the 
Luciferase Assay Substrate in Luciferase Assay Buffer and Stop & Glow reagent was 
prepared by adding 20 μl of Stop & Glow substrate into 1 ml of Stop & Glow buffer 
(S&G). The cell lysates were transferred to eppendorf tubes after 15 min of shaking 
and was centrifuged at 14000 x g for 30 sec to pellet down any cell debris. 20 μl of 
each supernatant was added into a white 96 well optical bottom plate (NUNC, 
#265302) followed by 100 μl of LARII and luciferase activity was measured using 
luminometer (2 sec delay followed by 10 sec measurement). After that, 100 μl of 
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S&G was added to the same sample immediately and the second renilla activity was 
measured. Triplicates were performed for all the samples and the Relative Luciferase 
Activity was calculated by dividing the luciferase reading with the renilla reading 
before results were analyzed.  
 
For knockdown experiment where MLL5β was first knocked down in HeLa cells 
before luciferase assay was performed, HeLa cells were first subjected to siRNA 
transfection as described in Section 2.2 for 24 hr before transfection of pGL3 vectors 
for luciferase assay was carried out as described earlier in this section. Cells were 
harvested 48 hr after pGL3 transfection for luciferase assay. 
 
For concentration gradient experiment, the concentration of DNA plasmid used was 
doubled in each sample. An increase of concentration is corresponding to an increase 
of the amount of DNA plasmid used (4.5 μg, 6 μg and 9 μg) without affecting the 
volume of the transfection reagent mix. 
 
2.13 Trypan blue dye exclusion assay 
To assess the survivability of the cells after siRNA transfection, trypan blue dye 
exclusion assay was performed. Cells were transfected with siRNA as stated in 
Section 2.2 and at desired time point post-transfection, cells were harvested as stated 
in Section 2.1 with slight modification. Cells were washed with PBS and PBS with 
unattached cells was kept and pelleted down through centrifugation at 2000 x g for 5 
min along with the trypsinized cells. Cells were then resuspended in PBS before 10 µl 
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of the cell suspension was added to 10 µl of trypan blue (Sigma-Aldrich 72-57-1) for 
counting by using haemocytometer. Live cells that were not stained by trypan blue 
and dead cells that were stained by trypan blue were both counted and the 
survivability of the cells were calculated as the percentage of the living cells divided 
by the total cells (both living and dead cells). Triplicates were performed for each 
sample. 
 
2.14 Senescence assay (Sigma C S0030-kit) 
HeLa cells were plated in 6-well plate and appropriate siRNA was transfected into the 
cells as described in Section 2.2. Cells were cultured for 10 days with a new siRNA 
transfection performed every 3 days. After 10 days, cell culture media was aspirated 
and cells in each well were washed with 1 ml 1x PBS carefully without detaching the 
cells.  1.5 ml of 1x Fixation Buffer was then added into each well and incubated at RT 
for 7 min. Staining Mixture was prepared during the incubation period which consists 
of the following components for every 10 ml: 1ml of 10x Staining Solution, 125 μl of 
Reagent B, 125 μl of Reagent C, 0.25 ml of X-gal solution and 8.50 ml of ultrapure 
water. The cells were washed with 1x PBS again for 3 times after fixation and 1 ml of 
Staining Mixture was added into each well. The plate was then parafilmed to prevent 
drying out and left incubated in 37 °C overnight in a non-CO2 enriched atmosphere. 
After staining, the Staining Mixture was replaced with 1x PBS and the number of 
senescence cells that were stained blue were calculated together with the total cells for 




2.15 Cytotoxicity assay 
To assess the toxicity caused by either drug such as cisplatin or siRNA; coupled with 
or without gamma irradiation; cytotoxicity assay using Cyto96 Non-Radioactive 
Cytotoxicity Assay (Promega G1780) was carried out. Cells were cultured in 48-well 
plate but not the outermost wells which were filled with PBS due to the higher 
evaporation rate at these wells. For each treatment, two sets of cells were needed 
where the first set is for the spontaneous release and the second set for maximum 
release. Each set was carried out in triplicates and a sample with just media without 
cells was prepared for the background control. For the cytotoxicity of siRNAs, cells 
were cultured as stated in Section 2.1 and siRNAs were transfected into the cells as 
stated in Section 2.2. At 48 hr post-transfection, the media was changed to fresh 
media and for the irradiation treatment, cells were subjected to 5 Gy of gamma 
irradiation through the irradiation chamber in CIBA Lab, Department of Physics, 
National University of Singapore. On the other hand, for the cytotoxicity of cisplatin, 
cells were cultured as stated in Section 2.1 for 24 hr before treated with cisplatin 
(Sigma-Aldrich, P4394), according to the indicated dosage from a 6 mM stock 
dissolved in water, for 6 hr. The cells were washed with PBS once before fresh drug-
free media was added and for the irradiation treatment samples, cells were subjected 
to 5 Gy of gamma irradiation as described before. For both siRNA and cisplatin 
samples, the cells were harvested for cytotoxicity assay 24 hr after the gamma 
irradiation treatment.  
 
20 μl of 10 X Lysis Solution was added to the maximum release wells to lyse the cells 
for 45 min in the 37 °C incubator. Plate was then centrifuged at 250 x g for 4 min 
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before 50 μl from all wells was transferred to a fresh 96-well flat-bottom plate (Nunc). 
Reagent Mix was reconstituted by mixing 12 ml of the Assay Buffer with a bottle of 
Substrate Mix and 50 μl was added into each well. Plate was then incubated at RT for 
30 min, protected from light before 50 μl of Stop Solution was added into each well. 
Large bubbles formed during the pipetting were removed by using a syringe needle 
and absorbance at 492 nm was measured using spectrometer (Tecan) within 1 hr after 
addition of Stop Solution. After deducting the background control, percentage 
cytotoxicity was calculated by dividing the spontaneous release against the maximum 
release for all of the samples.  
 
For the rescue experiment, MLL5β or empty vector was exogenously introduced into 
HeLa cells using calcium phosphate transfection as described in Section 2.4. The cell 
culture media was changed to media with 40 μM cisplatin 24 hr post-transfection for 
6 hr before cells were washed twice with 1x PBS and replaced by cell culture media 
without drug. Cytotoxicity assay was carried out 48 hr post-transfection. 
 
2.16 Clonogenic and soft agar assay 
To achieve a stable knockdown of the gene of interest, short hairpin RNA (shRNA) of 
MLL5β, HPV18 E6 and HPV18 E7 were generated using pSilencer2.1-U6 Hygro 
(Invitrogen) as the backbone. siRNA sequences were converted to shRNA through 
web-based insert design tool by Invitrogen. The sequences of the oligonucleotides 




Table 12: Oligonucleotides for shRNA generation 























The oligonucleotides were diluted into 1 μg/μl and 2 μl of forward and reverse 
oligonucleotides each were added into 46 μl of 1 X DNA Annealing Solution as the 
annealing mixture. The mixture was heated to 90 °C for 3 min before placed into a 
37 °C incubator for 1 hr. After incubation, 5 μl of the annealing mixture was diluted 
with 45 μl of nuclease-free water and ligation was set up as followed: 1 μl of diluted 
annealing mixture, 6 μl of nuclease-free water, 1 μl of 10 X T4 DNA Ligase Buffer, 1 
μl of pSilencer vector and 1 μl of T4 DNA ligase (5 U/μl) and incubated at RT for 2 
hr before transformed into competent cells as stated in Section 2.10. Successful clones 
were confirmed by sequencing. 
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The shRNA was transfected into cells as stated in Section 2.4 and media with 500 
μg/ml hygromycin was used to select for successful transfected cells after 24 hr. The 
cells were under hygromycin selection for 72 hr before the surviving cells were 
harvested and counted using haemocytometer for the downstream assays. For 
clonogenic assay, 400 cells were added into each well of a 6-well plate with 
hygromycin media (500 μg/ml). The plate was incubated for 20 days with changing of 
fresh hygromycin media every 3 days. The colonies formed were fixed with methanol 
and stained with 0.5 % crystal violet (Sigma-Aldrich). Colonies were observed under 
microscope and colony that was more than 50 cells was counted as a successful clone 
and the percentage of surviving clone was calculated as the number of successful 
clones over the total cells added. 
 
On the other hand, for soft agar assay, 2 X DMEM, 0.6 and 0.8 % agarose solution 
were prepared and kept warm at 40 °C.  500 μl of 2 X DMEM was mixed with 500 μl 
of 0.8 % agarose and pipetted into a 6-well plate as the base layer for each well. The 
base layer was allowed to cool down and solidify over 30 min in an incubator. 800 
cells were resuspended in 500 μl of 2 X DMEM and mixed with 500 μl of 0.6 % 
agarose before added on top of the settled base layer. 500 μl of hygromycin media 
was added to each well after the top layer has cooled down and formed a semi-solid 
matrix. The plate was incubated for 30 days with the addition of 500 μl hygromycin 





2.17 In vivo mouse xenograft assay 
Mouse xenograft was performed by GenScript in Nanjing, China. Forty five female, 
BALB/c nude mice from 6 to 8 weeks old were used and 5 million HeLa cells were 
injected to the right flank of the mice. Tumor developed was monitored and 28 mice 
with tumor size of around 150 mm3 were assigned randomly into 4 groups of 6 mice 
each. siRNAs used were identical to the siRNAs listed in Table 1. For each mouse, 10 
μg of siRNA was used together with 1.6 μl of in vivo-jetPEI transfection reagent 
(Polyplus Transfection 201-50G). Hence, transfection reagent for all of the 7 mice in 
one group was prepared as followed: 70 μg of siRNA was dissolved in 175 μl of 10 % 
glucose solution before sterile water was added to make up to 350 μl. 11.2 μl of in 
vivo-jetPEI was added to 175 μl of 10 % glucose and sterile water was added to make 
up to 350 μl. The diluted siRNA was then added to the diluted in vivo-jetPEI, mixed 
well and incubated at RT for 15 min. 100 μl of the transfection reagent was injected to 
each mouse directly at the mouse tumor site. The intratumoral injection was done in 
several points on the tumor for better efficiency. siRNA injection was done in every 
other day for a total period of 20 days and the tumor size was monitored throughout 
the period and up to 23 days. Mice were sacrificed after 23 days and tumor was 





3. Results: A novel MLL5 isoform that is essential to 




We noted a marked accumulation of p53 protein in HPV18-positive HeLa cells upon 
knockdown of MLL5 expression by small interfering RNA. This p53 accumulation 
was not observed in other HPV-negative cell lines used such as HCT116, U2OS and 
WI-38 (Cheng et al, 2008a). HeLa is a HPV-positive cell line that contains part of the 
HPV18 genome integrated into its genome and expresses oncoproteins such as E6 and 
E7. Besides that, E6 has been known to target p53 for degradation via the formation 
of a complex with E3 ubiquitin-protein ligase E6AP; therefore wild-type p53 proteins 
are barely detected in cervical cancer cells despite the presence of detectable amounts 
of p53 mRNA transcripts (Thomas et al, 1999). This led us to speculate that 
knockdown of MLL5 may have an effect on the expression of E6 protein in HPV-
positive cell lines. Therefore, investigations about the possible role of MLL5 in HPV 
tumorigenesis were carried out. 
 
3.2 Knockdown of MLL5 in human HPV16/18-positive cervical cancer cell lines 
reduces the expression level of E6 and E7 oncoproteins 
HPV-18 positive HeLa cells were transfected with MLL5-specific siRNA, targeting 
the N-terminal region of MLL5 mRNA (MLL5-siRNA#1, Table 1), for up to 72 hr 
before whole cell lysates were collected for Western blot analysis. Indeed, HPV18-E6 
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protein level in HeLa was found to decrease in a time-dependent manner (Figure 6, 
left panel). HPV18-E6 protein level decreased after 24 hr of siRNA treatment and was 
almost depleted after 72 hr; simultaneously, we saw an accumulation of p53 protein 
levels, which continued till the last time point of 72 hr. Similar results were observed 
in two other HPV-16 positive human cervical cancer cell lines CaSki and SiHa 
(Figure 6, middle and right panel). Decrease in E6 protein expression upon 
knockdown of MLL5 was less likely to be a result of the disruption of E6-E6AP-p53 
complex because the protein level of E6AP remained at a similar level regardless of 





Figure 6. MLL5 knockdown leads to down-regulations of E6 and E7 oncoproteins in HPV16/18-positive cell lines. Expression of various 
proteins exposed to scrambled or MLL5 specific siRNA#1 in a time-dependent manner for HPV18-positive HeLa, HPV16-positive CaSki and 
SiHa. The cells were transfected with scrambled or MLL5-siRNA for indicated time period and harvested for Western blot analysis. β-actin is 




Since HPV E6 and E7 oncogenes are known to be transcribed under the control of the 
same promoter and are translated from a bicistronic mRNA (Schneider-Gadicke & 
Schwarz, 1986; Smotkin & Wettstein, 1986), the level of E7 protein and its known 
targeting protein, retinoblastoma (Rb) were examined. Studies have shown that upon 
E7 downregulation, Rb was activated to its hypo-phosphorylated form (Hwang et al, 
2002; Hamid et al, 2009). Interestingly, a significant decrease in HPV18-E7 protein 
and an increase in hypo-phosphorylated form of Rb were also detected in HeLa when 
MLL5 was knocked down (Figure 6). E7 protein was first observed to decrease after 
48 hr of MLL5 knocked down and was depleted after 72 hr. An inverse trend was 
seen in hypo-phoshporylated Rb where an accumulation of hypo-phosphorlyated Rb 
was seen 48 hr post knockdown and its level continued to increase till the last time 
point of 72 hr. A similar trend was also observed in CaSki and SiHa (Figure 6). In 
summary, our data demonstrated that MLL5 knockdown in both HPV16 and 18 
cervical cancer cell lines led to a reduction in the expressions of viral-oncoproteins E6 
and E7. This downregulation further caused an increase in key cell cycle regulators, 
p53 and hypo-phosphorylated pRb proteins. 
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3.3 Restoration of p53 protein only occurs in HeLa cells treated with siRNA 
targeting to the N-terminal region but not the central or C-terminal region of 
MLL5 mRNA 
To rule out the possibility of an off-target effect, besides the MLL5-siRNA#1 used in 
Figure 6, three other siRNAs targeting different sites spanning across MLL5 mRNA 
were employed. Their effects on the restoration of p53 protein were examined. 
Among the four siRNAs, two of them (#1 and #2) target the N-terminal region of 
MLL5 while the other two (#3 and #4) target the central and C-terminal regions of 
MLL5, respectively (Figure 7A). We had expected to see a similar restoration of p53 
with all four MLL5-siRNAs used. Surprisingly, massive p53 accumulation occurred 
only in the presence of MLL5-siRNA#1 and #2, even though MLL5 was knocked 
down with similar efficacy with all four siRNAs as revealed by Western blot analysis 
(Figure 7B). Based on this observation, we selected two siRNAs (#1 and #4) and 
repeated the experiment in the other two HPV16-positive cell lines CaSki and SiHa. 
Consistent with the previous data, massive p53 restoration only occurred in MLL5-
siRNA#1 but not MLL5-siRNA#4 in all three cell lines tested (Figure 7C). 
Nonetheless, a small but detectable amount of p53 protein was observed in MLL5-
siRNA#4-knocked down samples, which could be attributed to the effect of full-
length MLL5 knockdown as seen in our previous observations (Cheng et al, 2008a). 
 
Based on this observation, we attempted to discern the effect of MLL5-knockdown 
with MLL5-siRNA#1 and #4 on both E6 and E7 mRNA levels by semi-quantitative 
Real-Time PCR. Consistent with the Western blot results, a marked down-regulation 
of both E6 and E7 mRNA was observed in all three HPV-positive cell lines when 
MLL5-siRNA#1 was used but not in MLL5-siRNA#4 despite the comparable 
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knockdown efficiency of both siRNAs on MLL5 mRNA (Figure 7D). The role of E2 
which is a known E6/E7 repressor was disregarded, since E2 was shown to be absent 
in these HPV-positive cells due to the disruption of E2 gene upon the integration of 
HPV DNA (Schwarz et al, 1985).  
 
These observations led us to speculate that a MLL5 isoform comprising the N-
terminal region but lacking the central and C-terminal regions is present. We thus 
hypothesize that this putative shorter MLL5 isoform rather than the full-length MLL5 
plays a role in restoring p53 protein and inducing hypo-phophorylated Rb in 






Figure 7. N-terminal targeting MLL5-siRNAs restores p53 in HPV16/18-positive 
cervical cancer cell lines but not C-terminal targeting siRNAs. (A) Schematic 
representation of MLL5 and the regions MLL5-siRNAs target to. Arrows marked the 
position of each target region of the four siRNAs used. MLL5-siRNA#1 and #2 target 
the N-terminal region, MLL5-siRNA#3 targets the central region and MLL5-
siRNA#4 targets the C-terminal region of MLL5 mRNA. (B)  Western blot analysis of 
p53 level after knockdown of MLL5 in HeLa using four different siRNAs. (C) 
Western blot analysis of p53 level after knockdown of MLL5 in HeLa, CaSki and 
SiHa with scrambled- siRNA (SC), MLL5 N-terminal targeting siRNA (#1) or MLL5 
C-terminal targeting siRNA (#4). A common trend of p53 accumulation can be 
observed in MLL5-siRNA#1 but not in MLL5-siRNA#4 across different human 
cervical cell lines. (D) RT-PCR experiments using HeLa, CaSki and SiHa after 
various siRNA treatment. A marked reduction of E6 and E7 mRNA in HeLa, CaSki 
and SiHa cells after transfected with MLL5-siRNA#1 for 72 hr but not for MLL5-





3.4 Characterization of the novel MLL5 isoform 
To validate our hypothesis, 5’ and 3’ Rapid Amplification of cDNA Ends (RACE) 
were carried out to identify the isoform. Since MLL5-siRNA#1 was able to knock 
down the putative isoform, its position in exon 7 (GenBank accession number: 
NM_182931) was used as the priming site for the RACE-gene specific primers. For 5’ 
RACE, a PCR product of approximately 1000 bp was amplified from all six cell lines 
used, which comprises of both HPV-positive cell lines (HeLa, CaSki and SiHa) and 
HPV-negative cell lines (293T, HCT116 and U2OS) (Figure 8A). Upon sequencing, it 
confirmed that the amplicon obtained had no difference in the sequence as compared 
to the full-length MLL5, indicating that the putative MLL5 isoform has the same 5’ 
end as the full-length MLL5 up to exon 7. 
 
Subsequently, 3’ RACE was carried out to identify the 3’ end of the putative isoform. 
A forward primer specific to MLL5 start-codon was used along with a reverse primer 
that primed to the poly-A tail of the mRNA. Extension time was set to seven minutes, 
allowing for the complete amplification for the full-length MLL5. From the results 
(Figure 8B), all cell lines tested showed a 6-kb band which corresponds to the full-
length MLL5. Interestingly, an additional 1.6-kbp band can be observed in all the 
three HPV16/18-positive cell lines, CaSki, SiHa and HeLa. Upon sequencing and 
alignment with the MLL5 gene, it was found that the 1.6-kbp band has the same 
sequence as the full-length MLL5 from the start-codon up to part of exon 14 
(GenBank accession number: NM_182931), where it was truncated by a 26-bp 
sequence that introduced a stop codon and followed by a poly-A tail (Figure 8C & 
8D). We denoted this novel MLL5 isoform (503 amino acid) as MLL5β to differ it 
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from the one previously reported by Fujiki et al (2010) that was truncated at exon 15 
(609 amino acid). 
Figure 8. Identification of a novel MLL5 isoform. (A) Results of 5’ RACE with 
gene-specific reverse primers targeting at exon 7 of full-length MLL5. A 1-kb 
amplicon can be observed in all six cell lines. (B) Result of 3’ RACE with MLL5-
specific forward primer targeting at start codon of full-length MLL5 and reverse 
primer targeting at poly-A region. A 6-kb DNA band which corresponds to the full 
length MLL5 can be observed in all cell lines but an additional 1.6-kb band can only 
be observed in HeLa, CaSki and SiHa. (C) Characterization of the novel isoform 
MLL5β compared to full-length MLL5. Shaded box indicated the inserted 26-bp 
which introduced a stop codon. Filled triangles indicate the sequences used for the 
antigens of antibody α-MLL5-227 while opened triangle indicates that of antibody α-
MLL5-1157. (D) Characterization of MLL5β mRNA compared to full-length MLL5. 





Next, it would be intriguing to investigate whether MLL5β is exclusively present in 
HPV16/18-positive cell lines. A panel of human cancer cell lines and WI-38, a human 
diploid cell lines were chosen for this study. Semi-quantitative PCR was carried out 
with primers specifically designed to detect MLL5β mRNA. As shown in Figure 9A, 
MLL5β was only detected in HPV16/18-positive human cervical cancer cell lines, but 
not in other human cancer cell lines. In contrast, the full-length MLL5 was detectable 
in all cell lines. It is worthy to mention that MLL5β was not seen in the normal 
diploid cell line WI-38 and HPV-negative human cervical cancer cell line C33A.  
 
Furthermore, eight human primary cervical carcinoma specimens (at the late stage of 
the cervical carcinoma) were tested for MLL5Using MLL5gene-specific primer 
for cDNA synthesis, MLL5was successfully detected in all eight samples (Figure 
9B). More importantly, no band can be detected in HPV-negative C33A and HCT116 
cells even when gene-specific primer was used. HPV genotyping by PCR method 
(Zehbe & Wilander, 1996) was applied on the genomic DNA extracted from the eight 
specimens and it has been found that CC1, 2, 4, 5, 6 and 8 were HPV16-positive 
while CC3 was HPV18-positive. No amplicon can be detected from CC7, which may 
due to limitation of the test which has success detection rate of 95 %. Furthermore, 
3’RACE was performed on all eight human primary cervical carcinoma samples and 
the identical 26-bp sequences can be detected in all eight samples at the same location 
(Figure 9C). In summary, we have identified and characterized a novel MLL5 isoform 
which can only be detected in HPV16/18-positive cervical cancer cells lines and 







Figure 9. MLL5β was detected in HPV16/18-positive cervical cancer cell lines 
and primary cervical carcinoma samples. MLL5β presents in HPV16/18-positive 
cell lines but not in other human cell lines. Only RNA purified from HPV-positive 
cell lines HeLa, CaSki and SiHa but not in other HPV-negative cell lines showed 
successful amplification for MLL5, suggesting that MLL5β only present in 
HPV16/18-positive cell lines. (F) MLL5β can be detected in all eight human cervical 
cancer specimens (CC1 to CC8). MLL5β-specific primer was used for cDNA 
synthesis. GAPDH was used as loading control. (C) 3’RACE using oligo(dT)-
containing adaptor primer revealed that the 26-bp (sequences in red) can be identified 
in all eight specimens at the identical position with HeLa, CaSki and SiHa. (D) 
Protein sequences of the last 15 amino acids of MLL5β in all eight specimens with 
HeLa, CaSki and SiHa. Only one amino acid is different between MLL5β and MLL5. 
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3.5 MLL5β isoform is responsible for the restoration of p53 protein level through 
down-regulation of E6 and E7 transcripts 
From our earlier experiments, we had used the antibody against the central region of 
MLL5 (amino acid 1157-1170, designated as α-MLL5-1157) to probe for the full-
length MLL5. Knowing that the MLL5 isoform encodes for the protein sequence of 
MLL5 from N-terminus up to 503 amino acids, the α-MLL5-1157 antibodies may not 
be suitable for detecting the presence of the MLL5 protein. Instead, we employed α-
MLL5-227 antibody which was raised against the N-terminal region of MLL5 (amino 
acid 227-241, Deng et al., 2004) to probe for the MLL5 protein in HPV16/18-
positive cell lines. As shown in Figure 10A, a protein band migrating at approximate 
70-kDa position was successfully knocked down by both MLL5-siRNA#1 and #2 but 
not by the MLL5-siRNA#3 and #4. Importantly, knockdown of the 70-kDa MLL5β 
protein corresponded to the restoration of p53 levels.  
 
Next, a new siRNA duplex that specifically targets the 26-bp sequence exclusively 
found in MLL5β mRNA, designated as MLL5β-siRNA, was synthesized. MLL5β was 
successfully knocked down and this corresponded to an increase in p53 protein level 
in HeLa (Figure 10B). Besides that, we performed similar knockdown experiment on 
HPV-negative cells HCT116 and U2OS and confirmed that p53 accumulation only 
occurs in HPV-positive cells (Figure 10C). 
 
The effect of MLL5β-siRNA on E6/E7 genes expression was monitored using semi-
quantitative real-time PCR (Figure 10D). Consistent with our hypothesis, the E6/E7 
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levels were found to be significantly reduced in all three human cervical cancer cell 
lines when MLL5-siRNA was used (p<0.001). As MLL5-siRNA targeted to 26-bp 
sequence exclusively present in MLL5, the full-length MLL5 mRNA was not 
affected by the MLL5β-siRNA. 
 
Figure 10. Effects of MLL5β-knockdown on p53 protein level and E6/E7 mRNA 
level. (A) MLL5β can only be knocked down using MLL5-siRNA#1 and #2 and this 
corresponded to the p53 restorations in these two siRNAs treated cells but not in 
MLL5-siRNA #3 and #4 treated cells. (B) MLL5β was successfully knocked down by 
MLL5β-siRNA and this led to the restoration of p53. As expected, full-length MLL5 
was down-regulated by MLL5-siRNA#1 but not MLL5β-siRNA. (C) MLL5β-siRNA 
was introduced to knockdown HPV-positive HeLa cells and HPV-negative HCT116 
and U2OS cells for 72 hr before cell lysates were collected to probe for p53. 
Accumulation of p53 protein occurs exclusively in HeLa upon MLL5β knockdown. 
(D) Semi-quantitative RT-PCR analysis of HeLa, CaSki and SiHa after MLL5β-
siRNA knockdown. Consistent with the Western blot results, MLL5β-siRNA 




Subsequently, we asked whether exogenous expression of MLL5 can abrogate the 
MLL5β-siRNA-mediated p53 restoration. HeLa cells were treated with MLL5β-
siRNA for 24 hr before GFP-MLL5-FL (GFP-tagged full-length MLL5) or GFP-
MLL5β were over-transfected for 48 hr. The cells were then sorted on the basis of 
GFP expressions (sorting was carried out in Flowcytometry Laboratory Unit, National 
University Health System using BD FACSVantage SE) and lysed for Western blot 
analysis. GFP-MLL5 plasmid was mutated appropriately (indicated by asterisk) so 
that the expression cannot be inhibited by MLL5β-siRNA. As shown in Figure 11, the 
effect of p53 accumulation when MLL5β was knocked down cannot be observed 
when we over-expressed the uninhibitory GFP-MLL5β into the MLL5β-siRNA 
treated cells. This ‘rescue’ effect cannot be observed when GFP-MLL5-FL was over-
expressed, further proving that MLL5β but not MLL5-FL was responsible for the p53 





Figure 11. Rescue experiments to validate the specificity of the MLL5β-siRNA. 
The effect of p53 restoration can be rescued after uninhibitory MLL5β was introduced 
exogenously into MLL5β-siRNA treated HeLa cells. GFP-MLL5β was mutated 
(indicated by asterisk) so its expression is not inhabited by MLL5β-siRNA. 
 
 
Taken together, MLL5β, a novel MLL5 isoform exclusively present in HPV16/18-
positive cell lines, was successfully characterized.  Knockdown of MLL5β but not the 
full-length MLL5 was shown to restore p53 protein level through down-regulation of 





3.6 MLL5β activates HPV18 E6/E7 transcription through the regulation of LCR  
Previous studies have shown that proteins such as epidermal growth factor and 
interferon regulator factor-2 are able to regulate E6/E7 gene transcription through 
their regulatory region, termed as the long control region (LCR) or upstream 
regulatory region (URR) (Yasumoto et al, 1991; Lace et al, 2010). In Figure 12A, the 
position of the LCR is shown in the genomic map of HPV18, along with the viral 
genes. The regulatory region is rich in cis-regulatory elements, often act as binding 
sites for various transcription factors, and has been established that these play 
important roles in HPV gene expression and replication (Howley, 1991). Therefore, a 
dual-luciferase assay was carried out to address whether MLL5β is involved in the 
transcription regulation of bicistronic E6/E7 expression through the LCR. The 
complete region of HPV18 LCR starting from downstream of L1 gene to the origin of 
replication of E6/E7 (nucleotide number 7018 to 119, Figure 12A), was cloned into 
pGL3 vector.  
 
Next, HEK 293T cells were co-transfected with pGL3-HPV18LCR and one of the 
followings: pEGFP-empty, pEGFP-MLL5β or pEGFP-MLL5CT (GFP-tagged MLL5 
C-terminal region) for 48 hr, along with pRL-TK as an internal control. A HPV-
negative cell line HEK 293T was chosen for the luciferase experiment since it does 
not express endogenous MLL5β and it does not contain any copy of integrated 
HPV18-LCR in its genome. Therefore, any changes in the luciferase expression can 
be attributed directly to the effect of the exogenously expressed MLL5β. As shown in 
Figure 12B, relative luciferase activity was significantly increased only when GFP-
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tagged MLL5β was overexpressed (p<0.001), providing evidence that indeed MLL5β 
itself was able to activate the transcription of the LCR.  
 
We constructed various fragments of HPV18-LCR fused with pGL3 vector to dissect 
the region that is responsible for LCR activation through association with MLL5β. 
Relative luciferase activity of fragment A showed the largest decrease, suggesting that 
the distal region from nucleotides 7018 to 7305 of LCR contains the essential 
elements required for the activation of HPV18-LCR by MLLβ. A further decrease of 
relative luciferase activity in fragment D was observed and this could be contributed 
by a previously described E6/E7 activation element, the proximal AP-1 transcription 
factor binding sites located in the region between nucleotides 7605 to 7806 (Cripe et 
al, 1987; Chin et al, 1989). 
 
To demonstrate that MLLβ would interact with HPV18-LCR to regulate its 
transcriptional activity, chromatin immunoprecipitation experiment was set up. 
FLAG-MLL5β or FLAG-MLL5-CT was over-expressed in HeLa for 48 hr before the 
cells were cross-linked, sonicated and immunoprecipitation was carried out using the 
α-FLAG antibody or the α-mouse IgG antibody which serves as a negative control. 
The DNA eluates were used as the templates for PCR reactions. Primer sets spanning 
the region of interest identified from a previous experiment were designed as shown 
in Figure 12B. Significant enrichment of amplicons using primer pair 2 was observed 
in the α-FLAG-MLL5pulled-down eluates but not in others (Figure 12C), indicating 
an interaction between MLLβ and HPV18-LCR. Coupled with the previous luciferase 
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data, the region between nucleotides 7168 to 7350 consist of the element required for 





Figure 12. MLL5β interacts with HPV18-LCR to activate transcription. (A) 
Genetic map of HPV18 with various ORF of viral proteins denoted by arrows. E6 and 
E7 ORF is located immediately downstream adjacent to LCR of HPV18. (B) Dual 
luciferase assay using different fragments of HPV18-LCR cloned into pGL3 vector. 
Line 1 (nucleotide 7018 to 7239), 2 (nucleotide 7168 to 7350) and 3 (nucleotide 7378 
to 7576) represent the amplicons of primer sets used in ChIP. (C) Chromatin 
immunoprecipitation was carried out using the α-FLAG antibody or the α-mouse IgG 
antibody which serves as a negative control. The DNA eluates were used as the 
templates for PCR reactions using primer sets spanning the region of interest shown 
in Figure 4B. Only primer pair 2 showed significant enrichment indicating that 
MLL5β interacts with HPV-18 LCR at nucleotide 7168 to 7350. 
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However, in HeLa cells, relative luciferase activity is high even when GFP protein 
was over-expressed and exogenously expressed MLL5β does not further increase the 
relative luciferase activity (Figure 13A). It is likely that the endogenous 
MLL5present in HeLa cells has saturated the binding sites of the pGL3-HPV18-
LCR luciferase reporter.  
 
To test this hypothesis and illustrate the specific role MLL5β in HPV18-LCR 
activation in HeLa, we knocked down MLL5β before introducing pGL3-HPV18-LCR. 
A significant decrease in luciferase activity was observed when the endogenous 
MLL5β was diminished (p<0.001), suggesting that MLL5β plays an essential role in 
transcription activation of HPV18-LCR (Figure 13B). Besides this, we have shown 
that the amount of HPV18-LCR is the limiting factor for MLL5-mediated E6/E7 
activation. An increase in relative luciferase activity can be observed when 
concentration of pGL3-HPV18-LCR used was doubled in each subsequent sample 
(Figure 13C), indicating that the endogenous MLL5β readily binds to the exogenously 
introduced HPV18-LCR and therefore with more HPV18-LCR introduced, the higher 




Figure 13. Luciferase assay in HeLa cells. (A) HPV18-positive HeLa cells that 
expresses MLL5β endogenously were used as another cell line for luciferase assay. 
Similar basal level of luciferase activity obtained by GFP or GFP-MLL5β transfection 
indicates that the amount of HPV-LCR luciferase reporter vector is the limiting factor. 
Endogenous MLL5β presents excessively to the exogenously introduced HPV-LCR 
luciferase reporter, therefore luciferase activity did not further increase even when 
GFP- MLL5β is overexpressed. (B) MLL5β was knocked down for 24 hour before 
pGL3-HPV18-LCR was introduced in HeLa cells. Diminished endogenous MLL5β 
leads to a significant decrease in luciferase reading (p<0.001), indicating the 
importance of MLL5β in HPV18-LCR activation. (C) Increasing amount of pGL3-
HPV18-LCR luciferase reporter vector was exogenously introduced into HeLa. The 
luciferase assay was carried out to monitor the change in relative luciferase activity. 
An increase in plasmid amount corresponded to an increase in relative luciferase 
activity, indicating that the amount of HPV18-LCR present is the limiting factor in the 





We were also interested in the effect of MLL5β over-expression on the expression 
profile of E6 and E7 in HeLa cells. GFP-MLL5β was over-expressed in HeLa for 48 
hr followed by sorting (sorting was carried out in Flowcytometry Laboratory Unit, 
National University Health System using BD FACSVantage SE) and RNA was 
extracted from the cells for semi-quantitative RT-PCR detecting for HPV18-E6 and 
E7. However, although a significant increase can be observed in MLL5β mRNA level, 
no increase can be observed for both HPV18-E6 and E7 (results not shown), further 
indicating that MLL5β level has reached a saturation point in HeLa cells where all the 
endogenous HPV18-LCR binding sites have been activated by MLL5β. 
 
3.7 AP-1 transcription factor binding site is essential for the MLL5β-mediated 
activation of HPV18-LCR 
Since there is no conserved DNA-binding motif found on MLL5 (Emerling et al, 
2002) and a recent study has shown that MLL5 or its isoform can form complex with 
other proteins to exert its H3K4 activity (Fujiki et al, 2009; Sebastian et al, 2009), we 
hence hypothesized that one or more transcription factors might be involved in the 
MLL5β-mediated E6/E7 gene activation.  
 
To test this hypothesis and search for the putative transcription factor, an in silico 
study using PROMO virtual laboratory (Farre et al, 2003) was first conducted to 
screen for putative transcription factor binding sites on the HPV18-LCR fragment 
amplified by the primer pair 2 (nucleotides 7168 to 7350) employed in the ChIP 
experiment (Figure 12C). Four putative transcription factor binding sites with high 
matching scores were identified (Figure 14A). Further fragments of HPV18-LCR 
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were designed according to the distribution of the four transcription factor binding 
sites and cloned into pGL3-basic vector for dual-luciferase assays. Experiment was 
conducted in a similar set-up as previous luciferase assays (Section 3.5). Results 
showed no significant reduction in relative luciferase activity except for fragment A3, 
suggesting that the region of nucleotides 7310 to 7350 may comprise of candidate 
transcription factors associating with MLL5β for the activation of LCR. 
 
Two highly-matched transcription factor binding sites can be found in the fragment 
A3, namely AP-1 and SP-1. These two transcription factors have been previously 
reported to play a role in E6/E7 activation at the proximal region of LCR, between 
nucleotides 7605 to 7900 (Butz & Hoppe-Seyler, 1993; Demeret et al, 1994; Tan et al, 
1994); however, their roles at the distal region of LCR for E6/E7 activation have 
never been documented. To verify the involvement of these transcription factors in 
MLL5β-mediated activation, we generated pGL3 vectors carrying HPV18LCR with 
mutated AP-1 and SP-1 binding sites. These mutants were co-transfected with 
pEGFP-MLL5β for dual-luciferase assays and GFP-empty was used as a negative 
control. As shown in Figure 14B, AP-1 mutant showed a significant reduction 
(p<0.001) in relative luciferase activity but not SP-1 mutant, suggesting that AP-1 




Figure 14. Identification of the interacting partner of MLL5β in HPV18-LCR. (A) 
HPV18 LCR (nucleotide 7168 to 7350) is further fragmentized to narrow down 
possible interacting partners. No decrease in relative luciferase activity except 
fragment A3, suggesting that A3 is the shortest fragment that contains the putative 
interacting site. (B) DNA sequences of AP-1 and SP-1 binding sites in HPV18-LCR 
are shown. Mutants are indicated by letter ‘M’ and mutated sequences are indicated in 
bold. Binding motifs are shown by boxes. A decrease in relative luciferase activity by 





To investigate whether the MLL5β interacts with AP-1, immunoprecipitation was 
carried out. GFP-tagged MLL5β and FLAG-tagged AP-1 (Xie & Sabapathy, 2010) 
were exogenously expressed in HEK 293T cells before being pulled down by α-
FLAG-antibody. The heterodimer in the FLAG-tagged AP-1 used was c-Jun which is 
part of the heterodimer that form AP-1. c-Jun was chosen in the immunoprecipitation 
study since the other part of the heterodimer, c-Fos does not bind to DNA on its own 
and must form heterodimer with c-Jun to exert its effect. Since HEK 293T cells are 
HPV-negative and do not contain LCR fragments in its genome, HPV-18 LCR region 
was introduced exogenously into HEK 293T cells to provide the interaction site for 
MLL5β and AP-1, if any. Indeed, from the results shown in Figure 15A, GFP-MLL5β 
was observed to interact with FLAG-AP-1 in the presence of HPV-18 LCR. Without 
the exogenously expressed HPV-18 LCR, no interaction could be observed even 
though FLAG-AP-1 was successfully pulled down. 
 
Although studies have shown that full-length MLL5 lacks intrinsic H3K4 
methyltransferase activity (Nightingale et al, 2007; Madan et al, 2009), nonetheless, it 
possesses a SET domain which is a well-known domain that possesses HKMT 
activity (Nakamura et al, 2002). Moreover, four other MLL protein members were 
found to exert H3K4 methyltransferase activity through their SET domain (Yokoyama 
et al, 2004; Nightingale et al, 2007; Ansari & Mandal, 2010). Therefore, to 
investigate whether MLL5β activates E6/E7 transcription through the SET domain, 
SET-inactivated (Y358A) MLL5β mutant was constructed and used in the dual-
luciferase assay (Fujiki et al, 2009). Relative luciferase activity was found to decrease 
up to two fold when SET mutant was used (Figure 15B). However, only a marginal 
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decrease in the luciferase activity was observed when the concentration of 
exogenously-introduced SET mutant vector was increased.  
 
To further confirm the results, another SET-inactivated (C411A) MLL5β mutant was 
constructed along with a double mutant consists of both Y358A and C411A 
(Sebastian et al, 2009) and tested for its luciferase activity. Similarly, both C411A and 
double mutant showed decrease in relative luciferase activity comparable to Y358A 
mutant but did not deplete it completely (Figure 15C). These results indicated that 
SET domain plays a significant role in the activation of E6/E7 genes as the luciferase 
activity decreased when a SET mutant was used. However, due to the fact that 
luciferase activity was not depleted completely may suggest the involvement of other 





Figure 15. Interaction between MLL5β SET domain and AP-1 c-Jun. (A) Co-
immunoprecipitation experiments using GFP-MLL5β and FLAG-c-Jun in HEK293T 
cells. Pull-down was performed with anti-FLAG or anti-mouse IgG antibodies. 
Results showed interaction between MLL5β and AP-1 when HPV18-LCR was co-
transfected. (B) Dual-luciferase assays with inactivated SET domain mutant (Y358A). 
The decrease in relative luciferase activity corresponds to an increase in the 
concentration of the SET mutant vector used. GFP alone was used as a negative 
control (NC). (C) Dual-luciferase assays with another two inactivated SET domain 
mutants. Relative luciferase activity showed a two-fold decrease for all three mutants 




We have also tested whether HPV16-LCR has similar interactions with MLL5β 
through the distal AP-1 site. HPV16-LCR was cloned into pGL3 vector and similar 
luciferase experiment was set up in HPV16-positive SiHa cells (Section 3.5). The 
region from nucleotides 7018 to 7362, which contains a conserved AP-1 site, was 
found to be important for the MLL5-mediated E6/E7 transcription activation, as 
shown by the decrease in luciferase activity when fragment A of the HPV16-LCR was 
used (Figure 16A). Further confirmation by AP-1 mutant was carried out and indeed 
significant decrease of luciferase activity was observed when AP-1 mutant was used 
(p<0.001) (Figure 16B), indicating that AP-1 is essential in MLL5β-mediated E6/E7 
activation in HPV16-LCR. This result is similar to the HPV18-LCR (Figure 14), 
confirming that the distal AP-1 is important for at least both HPV16 and 18 in 
activating E6/E7 expression through MLL5β.  
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Figure 16. Identification of the interacting partner of MLL5β in HPV16-LCR. (A) 
HPV16-LCR was fragmentized and cloned into pGL3 vector and luciferase assay was 
carried out in HPV16-positive SiHa cells to determine the essential region where 
MLL5β interaction occurs. Similar to HPV18-LCR, distal region of HPV16-LCR 
(nucleotide 7018 to 7362) was found to be the essential region, indicated by the 
decrease in relative luciferase activity when the region was removed. (B) AP-1 mutant 
was generated and transfected into SiHa cells for luciferase assay. Similar to HPV18-
LCR, AP-1 was found to be essential in MLL5β-mediated gene activation, indicated 




To investigate whether MLL5β-mediated activation occurred in other HPV subtype 
beside HPV16 and 18, we obtained AP-1 mutants for HPV11-LCR, a low-risk HPV 
subtype from Simmons Comprehensive Cancer Center, University of Texas 
Southwestern Medical Center. Unlike HPV16 and 18, HPV11-LCR contains two 
distal AP-1 transcription factor binding sites (#1 and #2), from a total of five AP-1 
sites as shown in Figure 17A (Wang et al, 2011). Each of the sites was mutated in 
pGL3-HPV11-LCR, creating a total of five mutants, M1 to M5 which corresponds to 
AP-1 site #1 to #5. Luciferase assay was performed in HeLa cells using the pGL3-
HPV11-LCR mutants similar to the previous set up in Section 3.5. Interestingly, we 
observed a decrease in luciferase activity when either one of the distal AP-1 sites (#1 
and #2) was mutated but not on the other three AP-1 sites downstream (#3 to #5) 
(Figure 17B). This result suggested that MLL5β-mediated activation is not limited to 
high-risk HPV such as HPV16 and HPV18 but in low-risk subtype such as HPV11 as 
well. Besides that, this result also further proved that distal AP-1 site(s) is essential in 





Figure 17. Luciferase assay of HPV11-LCR in HeLa cells. (A) Diagram to show 
the distribution of the five AP-1 transcription factor binding sites in HPV11-LCR. #1 
and #2 sites are located in the distal region of the HPV11-LCR (Wang et al, 2011). (B) 
Luciferase assay of the five mutants (M1 to M5) along with a wild type (WT) of 
HPV11-LCR in HeLa cells. M1 and M2 showed a significant decrease in luciferase 





In summary, a novel isoform of MLL5, MLL5β was successfully identified. MLL5β 
plays a role in activating E6/E7 through the formation of a complex with AP-1 and 
binds to the AP-1 transcription factor binding site at the distal region of the HPV-18 
LCR. Upon depletion of MLL5β using siRNA, E6 and E7 are down-regulated, in both 
mRNA and protein level. This down-regulation leads to the restoration of p53 and 
hypo-phosphorylated Rb, which could re-establish the cell cycle checkpoint controls. 
However, more work needs to be done to assess the potential of MLL5β as a novel 
therapeutic target for HPV-related cervical cancers. These studies were outlined and 




4. Results: Mixed Lineage Leukemia 5 Isoform is a Potential 
Biomarker and Therapeutic Target for HPV-Associated 
Cervical Cancer 
 
4.1 Introduction  
We have shown that MLL5β-siRNA can specifically down-regulate MLL5β but not 
the full-length MLL5 and the down-regulation of MLL5β leads to the down-
regulation of both the transcription and translation of E6 and E7 oncogenes. Therefore, 
we speculated that MLL5β could be a novel therapeutic target for HPV-related 
cervical cancer. MLL5β-siRNA was used to knock down MLL5β in HPV-positive 
cell lines and its effect on the survival and proliferation of the cells was studied. 
Besides that, the effects of the MLL5β-siRNA were investigated in in vivo settings 
through mouse xenograft model to further illustrate the therapeutic potential of 
MLL5β. 
 
4.2 Knockdown of MLL5β in HPV16/18-positive cervical cancer cell lines  
To validate our hypothesis, HPV-positive cervical cancer cell lines SiHa (HPV16) and 
HeLa (HPV18) were treated with MLL5β-siRNA and the total cell number was 
monitored by trypan blue exclusion assay for up to 96 hr. HPV-negative cervical 
cancer cell lines C33A and normal diploid cells WI-38 were included to highlight the 
specificity of the MLL5β-siRNA. Besides that, siRNAs targeting E6 and E7 mRNA 
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for both HPV16 and HPV18 were added so that efficiency of different siRNAs 
towards suppressing cancer growth can be assessed. 
Indeed, as shown in Figure 18, MLL5β-siRNA treated HeLa and SiHa cells have 
much lower survivability compared to E6 and E7-siRNA alone after 72 hr (Figure 
18A) and 96 hr (Figure 18B), indicating a synergistic effect of the MLL5β-siRNA. 
Another interesting observation to take note of is that E6 and E7-siRNAs are subtype-
specific as HPV16 E6 and E7 siRNA do not suppress the growth of HeLa (HPV18-
positive) while HPV18 E6 and E7-siRNA do not suppress the growth of SiHa 
(HPV16-positive). In contrast, MLL5β-siRNA exerts its growth suppressing effect to 
both HeLa and SiHa in a comparable manner regardless of their HPV subtypes. As 
expected, none of these three siRNAs showed any growth suppressant activity 






Figure 18. MLL5β-siRNA suppresses the growth of HPV-positive cancer cells 
but not normal cells. HeLa, SiHa, C33A and WI-38 cells were each treated with 
scrambled, MLL5β, HPV16/18 E6 and E7-siRNA and trypan blue exclusion assay 
was used to determine the number of surviving cells after (A) 72 hr and (B) 96 hr. As 
SiHa is HPV16-positive while HeLa is HPV18-positive, E6 and E7-siRNAs of both 
subtypes were used. Graph was plotted by normalizing against the number of 
surviving cells in scrambled-treated samples. Asterisk indicate a significant decrease 










4.3 Reduction of cell survivability is due to the knockdown of both E6 and E7 
leading to apoptosis and senescence 
Upon observing the growth suppressing effect of MLL5β-siRNA on HeLa and SiHa 
cells, next we are interested in the mechanism behind the MLL5β-siRNA induced 
tumor suppressing effect. It has been established that E6-siRNA induces apoptosis in 
HPV-positive cell lines while E7-siRNA treatment leads to cell senescence. Seeing 
that MLL5β-siRNA can down-regulate both E6 and E7, we hypothesized that 
MLL5β-siRNA can induce both apoptosis and senescence, therefore creating a 
synergistic effect on tumor cell-growth suppressing activity compared to E6 and E7-
siRNA alone, as observed in Figure 18. HeLa cells were treated with MLL5β, HPV18 
E6 and E7-siRNAs and whole cell lysates were harvested at 24, 48 and 72 hr for 
Western blot. Cleaved-PARP, an apoptotic marker was used to determine the degree 
of apoptosis in the siRNA-treated cells. As expected, a marked accumulation of 
cleaved-PARP can be observed in MLL5β and HPV18 E6-siRNA treated cells but not 
in HPV18 E7-siRNA (Figure 19A).  
 
On the other hand, β-galactosidase, which is highly expressed and accumulated in 
senescence cells, was used to detect the degree of senescence in siRNA-treated cells. 
Senescence cells are stained blue due to the presence of β-galactosidase in its 
lysosome. Again the observation supports our hypothesis whereby only MLL5β and 
HPV18 E7-siRNA treated HeLa cells showed high percentage of senescence cell 
population compared to HPV18 E6-siRNA after a treatment period of 1 week (Figure 
19B). It is also interesting to note that after prolonged siRNA treatment, the number 
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of surviving cells in MLL5β-siRNA treated group is at least 5 times lower than other 
siRNA treatment. This again tallies with the results shown in Figure 18. 
 
Figure 19. MLL5β-siRNA induces both apoptosis and senescence pathway in 
HeLa cells.  (A) HeLa cells were treated with scrambled, MLL5β and HPV18 E6 and 
E7-siRNA before cell lysates were collected at 24, 48 and 72 hr interval for Western 
Blot analysis. Cleaved-PARP was used as a marker for apoptosis and β-actin was 
used as loading control. Cleaved-PARP was found to be accumulated in both MLL5β 
and E6-siRNA treated HeLa. (B) HeLa cells were treated with scrambled, MLL5β and 
HPV18 E6 and E7-siRNA for up to 1 week before cells was stained to detect 
senescence marker, β-galactosidase. Cell stained blue and marked by arrow indicates 
a senescence cell. Total cell number and total of senescence cells were counted and 
plot into graph. Higher percentage of senescence cells was observed in both MLL5β 




4.4 MLL5β-siRNA reduces the oncogenic properties of HeLa cells in in vitro 
assays 
To further assess the effectiveness of MLL5β-siRNA as a therapeutic agent for 
HPV16/18-positive cervical cancer, we performed in vitro assay for all MLL5β, E6 
and E7-siRNAs to check the anti-tumour effect. First the siRNAs were cloned into 
pSilencer vector to create shRNA construct for each MLL5β, E6 and E7. This is to 
achieve a more sustainable and stable knockdown of the gene of interest over a period 
of time. Besides that, shRNA transfection enables the screening of successfully 
transfected cells, in our case by using hygromycin drug. Clonogenic assay was 
performed to test the potency of the shRNAs on the survival and proliferation of the 
HeLa cells. As shown in Figure 20A, all three shRNAs used were found to be able to 
significantly reduce the number of colonies formed after 20 days but MLL5β-shRNA 
was the most effective one with the reduction of more than 90 % as compared to just 
pSilencer vector alone (empty) (p<0.001).  
 
Another in vitro assay performed is the soft agar assay, where the effect of shRNA 
against anchorage-independent growth was measured. Anchorage-independent growth 
is one of the hallmarks of cancer transformation, making soft agar assay the most 
accurate and stringent in vitro assay for detecting the malignant transformation ability 
of the cells. From Figure 20B, we can observe that upon treatment of all three MLL5β, 
E6 and E7-shRNAs of 30 days, HeLa cells failed to form any significant colonies 
compared to pSilencer vector alone (empty). Further inspection of the colonies 
formed under microscope (Figure 20C), we can observe that HeLa cells under HPV18 
E7-shRNA treatment have slightly bigger colonies (pointed by arrows) than MLL5β 
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and HPV18 E6-shRNA, suggesting that E7-siRNA does not induce apoptosis but 
senescence, since cells stopped replicating after the effect of the siRNA, creating a 
small colony. On the other hand, upon E6 and MLL5β-shRNA treatment, cells 
undergo apoptosis rapidly, leading to the death of the cells before it can proliferate 




Figure 20. MLL5β-siRNA reduces the cancer transformation ability of HeLa. (A) 
HeLa cells were treated with pSilencer vector alone (empty), MLL5β and HPV18 E6 
101 
 
and E7-shRNA and screened with hygromycin drug. The successfully transfected 
cells were then harvested and 400 cells of each treatment were plated into a 6 well 
plate to grow. Percentage of surviving colonies were then calculated and plotted into 
graph after 30 days. MLL5β-shRNA treated HeLa has significant reduced colonies 
compared to others (p<0.001). (B) HeLa cells were treated as previous experiment but 
800 cells were resuspended in 0.3 % agarose gel with culture media in 6 well plate. 
Number of colonies formed was noted after staining by crystal violet to facilitate the 
viewing of colonies. No visible colonies can be observed after treatment of MLL5β, 
E6 or E7-shRNA. 
 
 
4.5 MLL5β-siRNA exhibits anti-cancer effect in a in vivo assay 
After assessing the effect of MLL5β-siRNA in vitro, we are interested to investigate 
whether MLL5β-siRNA exhibits similar effect in vivo. By outsourcing the in vivo 
experiment to GenScript (China), we established a mouse system where a tumor is 
induced by subcutaneous injection of HeLa cells in immunodeficient mouse. MLL5β, 
E6 and E7 siRNAs were then injected into the tumor every other day for a period of 
20 days and the tumor size was monitored throughout the period. The system of tumor 
induction before siRNA treatment closely mimics the actual situation of the cancer 
compared to tumor induction using shRNA-treated cells. Consistent with the in vitro 
results, MLL5β-siRNA showed the highest tumor suppressor ability (p=0.001) 
compared to E6 (p=0.05) and E7 (p=0.15) alone (Figure 21A). After 20 days, the 
average of the tumor size treated by MLL5β-siRNA was decreased to 60 % of the 
scrambled-siRNA treated tumor, comparing to 70 % by E6-siRNA and 80 % by E7-
siRNA.  
 
A total of 6 mice was used in each treatment group and each of the tumors was 
excised and weighed after the mice were sacrificed (Figure 21B). A graph of the 
average tumor weight for each of the treatment group was plotted (Figure 21C) and 
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consistent with the tumor grow curve in Figure 21A, MLL5β-siRNA treated tumor 
was significantly smaller and lighter compared to scrambled-siRNA (p=0.002), E6-
siRNA (p=0.2) and E7-siRNA (p=0.01). MLL5β-siRNA treated tumor showed 
significant decrease in both size and weight in the in vivo setting using mouse 
xenograft. RNA was extracted from each of the tumors and fold change of the gene of 
interest in each group was determined to evaluate the efficiency of the siRNAs in vivo. 
All of the genes of interest were down-regulated by at least 10 folds (Figure 22), 





Figure 21. MLL5β-siRNA suppressed growth of HeLa-induced xenografts in 
nude mice. HeLa cells were used to induce tumor in nude mice and scrambled, 
MLL5β, E6 and E7-siRNAs were injected via intratumoral injection. siRNA was 
injected every other day for 20 days and size of the tumors was monitored. Upon 
completion of the 20 days treatment, mice were sacrificed and the tumors were 
excised for weighing and RNA study. (A) The effect of scrambled, MLL5β, E6 and 
E7-siRNAs on the average volume of the tumor in the 20-days treatment period. 
MLL5β- siRNA treated tumor was reduced to 60 % of the scrambled-siRNA treated 
tumor, compared to 70 % and 80 % of E6 and E7-siRNA respectively. (B) Each of the 
treatment group consists of 6 mice and the excised tumor for each mouse in each 
group was shown. (C) Average weight of the tumors in each treatment group was 
calculated and plotted in a graph. Consistent to the volume of tumors, MLL5β-siRNA 





Figure 22. Verification of the knockdown efficiency of the gene of interest in an 
in vivo study. RNA was extracted from the tumors of every mouse used in each group 
of studies and the expression of their respective gene of interest was measured using 
semi quantitative RT-PCR. Results were normalized against the expression of gene of 
interest in the scrambled-siRNA treated mouse group. Down-regulation of at least 10 




4.6 MLL5β-siRNA treatment sensitizes HPV16/18-positive cervical cell lines 
towards gamma irradiation 
Currently the mechanism behind the anti-cancer effect of the chemoradiotherapy 
using cisplatin remains unclear. p53 is believed to be triggered in the presence of 
these DNA damaging drug and gamma irradiation further enhance the activation of 
p53-dependent apoptosis, thereby creating a sensitization effect of cisplatin-treated 
cells towards gamma irradiation. By using lactose dehydrogenase (LDH) based 
cytotoxicity assay, which detects the LDH released into the media by dead cells, we 
checked the cytotoxicity level caused by different cisplatin concentration on HeLa, 
SiHa, C33A and WI-38 cells. Besides that, gamma irradiation was included to show 
the sensitization effect by the cisplatin drug. As shown in Figure 23, cisplatin with a 
concentration as low as 5 µM led to increased cytotoxicity level in all 4 cell lines 
tested, regardless of normal or cancer cells. However, cisplatin-induced sensitization 
effect can only be observed in both HPV-positive HeLa and SiHa cells. 
 
Next, we carried out similar cytotoxicity assay but using siRNA treatment instead of 
cisplatin.  From Figure 24, we can see that MLL5β and E6-siRNA treatment in HeLa 
and SiHa showed similar sensitization effect as cisplatin but not E7-siRNA, as the 
subsequent gamma irradiation treatment after cisplatin treatment caused an elevated 
cytotoxicity effect to the cells compared to cells without cisplatin treatment. Moreover, 
similar to the previous trypan blue exclusion assay (Figure 18), MLL5β-siRNA is 
highly specific to exert its effect only on HPV16/18-positive cervical cancer cells but 
not on normal cells, as the cytotoxicity caused by MLL5β-siRNA treatment on normal 
cells was maintained at a low level. As expected, the sensitization effect exerted by 
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E6-siRNA was found to be subtype-specific, where HPV16 E6-siRNA has no effect 
on HeLa cells and HPV18 E6-siRNA has no effect on SiHa cells. 
 
Figure 23. Cisplatin sensitizes HPV16/18-positive cell lines towards gamma 
irradiation.  Cytotoxicity assay was carried out to assess the effect of cisplatin on 





Figure 24. MLL5β-siRNA sensitizes HPV16/18-positive cell lines towards gamma irradiation.  Cytotoxicity assay was carried out to assess 
the effect of scrambled, MLL5β, E6 and E7-siRNAs on HeLa, SiHa, C33A and WI-38 cells, with or without gamma irradiation. Similar to 
Figure 18, E6 and E7-siRNAs of both HPV16 and HPV18 were used.
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4.7 MLL5β plays a role in cisplatin-induced anti-cancer effect 
Comparing the results of cytotoxicity assay using cisplatin and MLL5β-siRNA 
(Figure 23 and 24), we observed that the results were comparable to each other. Both 
cisplatin and MLL5β-siRNA were able to increase cytotoxicity level and sensitize the 
HPV16/18-positive cervical cancer cells towards gamma irradiation. Hence, we 
hypothesized that MLL5β may play a role in the cisplatin-induced anti-cancer effect. 
To validate our hypothesis, we performed quantitative RT-PCR to monitor the change 
in MLL5β, E6 and E7 mRNA level upon cisplatin treatment in HeLa and SiHa. As 
shown in Figure 25A, a decrease in all MLL5β, E6 and E7 mRNA was observed 
when the cells were treated with cisplatin. The degree of down-regulation 
corresponded to the concentration of cisplatin used, where a more significant decrease 
was observed when higher concentration of cisplatin was used. 
 
Next, to verify that MLL5β involved in the molecular mechanism where cisplatin 
exerts its anti-cancer property, a rescue experiment was carried out. First, MLL5β was 
exogenously expressed in HeLa cells for 24 hr before treated with 40 μM cisplatin for 
6 hr. After which the cells were subjected to gamma irradiation of 5 Gy and 
cytotoxicity assay was carried out 24 hr post-irradiation. From Figure 25B, we can 
observe that when MLL5β was introduced exogenously to cisplatin treated HeLa cells, 
the sensitization effect that should be observed after gamma irradiation treatment was 
‘rescued’, where the sensitization effect can no longer be detected. An empty vector 
which does not contain MLL5β was transfected into cisplatin treated HeLa cells as 
control. This rescue experiment further illustrates the role of MLL5β in the 
therapeutic effect of cisplatin. Therefore, by targeting the MLL5β that is specific to 
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HPV16/18-positive cells, we hope to achieve therapeutic effect comparable to 
cisplatin yet to have less adverse effects caused by the non-specific nature of cisplatin. 
This discovery could be important in the search of a better therapy for cervical cancer. 
 
Figure 25. MLL5β is involved in the cisplatin-induced anti-cancer effect. (A) 
HeLa and SiHa cells were treated with cisplatin before RNA was extracted through 
TRIZol, Quantitaive RT-PCR was carried out to determine the effect of cisplatin 
treatment on MLL5β, E6 and E7 mRNA level. (B) Rescue experiment to confirm 
MLL5β involvement in the therapeutic effect of cisplatin. HeLa cells were treated 
with cisplatin and MLL5β was introduced exogenously into the cells before gamma 
irradiation. Introduction of MLL5β prevents the sensitization effect caused by 







5.1 Summary of results 
In this study, we identified a novel MLL5 isoform, MLL5β, resulting from an 
additional 26 nucleotides that introduces a stop codon in exon 14 of MLL5 mRNA 
(Figure 8). The truncated MLL5isoform encoded a 503-amino-acid polypeptide that 
is exclusively present in HPV16/18-positive cervical cancer cells and can be detected 
in human primary cervical carcinoma (Figure 9). MLL5isoform associates with AP-
1 binding site located at nucleotide 7326 of the distal region of HPV18 LCR, 
upstream of the E6 and E7 promoter site (Figure 14).  The association with AP-1 
transcriptional factor is essential for the MLL5β-mediated bicistronic E6/E7 gene 
expression. Knockdown of MLL5isoform led to down-regulation of both E6 and E7 
oncoproteins, resulting in the restoration of p53 protein levels and a reduction in Rb 
phosphorylation (Figure 6). This is the first report to describe the presence of the 
novel MLL5β isoform and to illustrate the involvement of MLL5β in HPV16/18-
related cervical cancers. 
 
Besides that, we reported the pro-apoptotic and growth suppressing properties of 
MLL5β-siRNA on HeLa and SiHa cells. MLL5β-siRNA has been found to promote 
cell death and suppressing the growth of HPV16/18-positive cervical cancer cells, 
both in vitro through trypan blue assay, clonogenic assay and soft-agar assay and in 
vivo through a mouse xenograft study (Figure 18, 20 and 21). These anti-cancer 
properties were found to be related to pro-apoptosis and pro-senescence properties 
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displayed by MLL5β-siRNA treatment, due to its ability to down-regulate both E6 
and E7, where knocking down of E6 and E7 has been established to promote 
apoptosis and senescence respectively (Figure 19). The effectiveness of MLL5β-
siRNA treatment coupled with gamma irradiation was also compared with the current 
gold standard of cervical cancer treatment which involved chemoradiotherapy using 
platinum-based drug such as cisplatin (Figure 23). MLL5β-siRNA has been found to 
sensitize cancer cells towards gamma irradiation similar to cisplatin treatment which 
the mechanism involved in its therapeutic effect is yet to be fully understood (Figure 
24). By using semi-quantitative RT-PCR and rescue assays, MLL5β has been found 
to directly involve in the anti-cancer property of cisplatin treatment (Figure 25). This 
study is the first to assess the potential of MLL5β-siRNA as a new therapeutic target 
for HPV16/18-positive human cervical cancer. 
 
5.2 MLL5β as a novel activator of HPV16/18-E6/E7 expressions 
Given the fact that viruses often cause diseases when they enter host cells and 'hijack' 
the important cellular apparatus to redirect the cellular functions for their benefits, it is 
possible that the induction of MLL5β isoform may be an invasive strategy employed 
by HPV to regulate E6/E7 promoter activity (Figure 26). MLL5β interacts with AP-1 
transcription factor and recognizes the AP-1 binding site on nucleotide 7326 of the 
distal region of LCR (Figure 26, dashed area). The SET domain in MLL5β was found 
to play a role in the activation. However, when SET domain was inactivated, the 
effect of E6/E7 gene activation was not depleted completely (Figure 15), suggesting 
that besides interaction with AP-1, other proteins may be required to play a 
cooperative role for the E6/E7 activation. It is possible that there might be an 
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unidentified post-translational regulation on MLL5 isoform which is required for full 
activation activity. Various studies have shown the importance of post-translational 
modification of MLL5 such as GlcNAcylation (Fujiki et al, 2009) and 
phosphorylation (Liu et al, 2010) in exerting its effects. When MLL5β was depleted 
through transient siRNA knockdown, no MLL5β-AP-1 complex can be formed, 
leading to the absence of the interaction with LCR. This resulted in down-regulation 
of both E6/E7 transcript as revealed by RT-PCR (Figure 10) and Western blot 





Figure 26. A proposed model for the molecular mechanism of MLL5β in 
regulating E6/E7 gene activation. Full-length MLL5 (1858 amino acid) consists of 
N-terminal region (NT), central domain (CD) and C-terminal region (CT). Both PHD 
and SET domains can be found within the N-terminal region of full-length MLL5 and 
the N-terminal of MLL5β. LCR region of HPV18 is located between the L1 and 
E6/E7 ORF and it can be divided into three regions which consist of a distal region 




Our current model raised an interesting question of the possible mechanism behind 
MLL5β derivation. We have tried to map the exact chromosomal location of this 26-
bp fragment through bioinformatics search. However, no significant and meaningful 
sequence match of this 26-bp fragment with HPV genome or human genome can be 
found. Besides that, by using HeLa genomic DNA as a template and a forward or 
reverse primer that is specific to the 26-bp fragment along with an array of primers 
that bind to each intron of MLL5 gene, we attempted to fish out possible integration 
site of the 26-bp fragment in the MLL5 gene. However, no visible band can be 
detected, suggesting that there is no integration within the MLL5 gene, or the 
integration site does not contain the sequences recognized by the 26-bp-specific 
primers.  
 
Hence, we hypothesized that MLL5β is generated through a more complicated 
process than simply a result of HPV infection and integration. For instance, DNA 
double stand break (DSB) repair enzymes are involved in viral integration sites and 
studies have shown that deficiencies in some DSB repair enzymes caused aberrant 
junction sequences at the integration sites (Sakurai et al, 2009; Smith et al, 2009). 
This possible aberration adds on difficulty in relying on genomic database to identify 
the alternative splicing process or design appropriate primers for PCR reactions. In 
addition, current evidences show that such integration is a random event but common 
DNA fragile sites are more susceptible to the integration event (Thorland et al, 2000). 
If the generation of MLL5β is indeed a result of HPV integration, MLL5 locus is 
likely located near the common DNA fragile site. However, it is still difficult to 
explain how the HPV integration can lead to the same 26-bp at the 3’ end of the 
MLL5β transcript in all 8 primary patient samples. We hence suspect that there might 
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be other alternative mechanisms leading to the generation of MLL5β. Based on the 
fact that the 26bp RNA sequence does not match exactly with any published genomic 
DNA sequences and this 26-bp lacks the canonical pattern of 3’UTR sequence, RNA 
editing may be the alternative explanation for such short region modifications in the 
3’end of MLL5β RNA (Caudevilla et al, 1998; Li et al, 2008). These changes may 
arise from substitution or insertion/deletion RNA editing; however, more work has to 
be done to explore the possibility. 
 
Besides that, a recent study has shown that viral infection can induce novel isoform of 
endogenously expressed protein to facilitate its own survival and continuous 
replication through alternative splicing (Ku et al, 2010). SF2/ASF, a key splicing 
regulator, has been found to be up-regulated by HPV infection (Mole et al, 2009) and 
this could imply that HPV infection may have an effect on normal alternative splicing 
machinery. Furthermore, a novel gene APM-1 which is a fusion of the HPV and a 
human gene has been reported, further demonstrating the possible effect of HPV 
genome integration on human genes (Reuter et al, 1998). These examples illustrate 
the complex mechanism that may play a role in the derivation of MLL5β and further 
studies are required before any feasible conclusion can be drawn. 
 
Ubiquitous transcription factors such as AP-1 and SP-1 have well-established roles in 
HPV transcription regulation (Cripe et al, 1990; Gloss & Bernard, 1990; Thierry et al, 
1992).  As shown in Figure 26, the distal region (dashed area) of LCR contains 
transcription termination signal while the central region (grey area) contains majority 
of the transcription factor binding sites termed specific enhancer region (Cripe et al, 
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1987; Chin et al, 1989). The proximal region (chequered area) contains early 
promoter and the origin of replication (Demeret et al, 1994). In our study, we 
identified the distal AP-1 binding site at nucleotide 7326 as the important partner for 
MLL5β to interact with LCR. Only this AP-1 site plays an essential role in the 
transcription activation by MLL5β and this activation is at least five-fold stronger 
than the other two  previously reported AP-1 sites which are located at the central 
region (nucleotide 7609 and 7793) (Cripe et al, 1987; Chin et al, 1989) (Figure 12B). 
This could be attributed to the role of the chromatin structure in protecting the AP-1 
binding sites at the central region from exposure to the AP-1 transcription factor but 
not the AP-1 at the distal region (Stunkel & Bernard, 1999).  Moreover, we have 
shown that this AP-1 site is important in HPV16 (Figure 16) and HPV11 (Figure 17) 
and it is conserved in most of the other subtypes of HPV regardless of high or low-
risk (Figure 27). These findings illustrate the identification of a novel AP-1 binding 
site which activates E6/E7 through formation of MLL5β-AP-1 complex. 
 
The mechanism behind the E6/E7 gene activation by MLL5β but not full-length 
MLL5 despite containing the almost identical amino acid sequences (1 amino acid 
difference) remains unclear. This is similar to another MLL5 isoform reported by 
Fujiki et al where the isoform was found to co-activate RARα but not the full-length 
MLL5 (Fujiki et al, 2009). A possible explanation could be the full-length MLL5 C-
terminal region blocks the active site essential for the activation through formation of 
secondary structure. Therefore, when the C-terminal region is lost in the shorter 
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5.3 MLL5β as a novel biomarker and therapeutic target for HPV-related cancers 
Over the years, evidences have shown that HPV is associated with several cancers 
including cervical, anogenital and a subset of neck cancers (Walboomers et al., 1999; 
zur Hausen., 2002; Weinberger et al., 2006). In particular, HPV infection had been 
implicated as the causative agent for cervical cancer since more than 95 % of cervical 
cancer biopsies contain high risk HPV genomes. In recent years, advances in medical 
therapies for cervical cancer including the immunisation of females with HPV 
vaccines to provide them with protection against virus-induced tumours before they 
become sexually-active, as the HPV is spread via sexual contact. The bivalent 
HPV16/18 vaccine produced by GSK, Cervarix and quadrivalent HPV6/11/16/18 
vaccine produced by Merck, Gardasil induce the production of antibodies against the 
major capsid protein of the respective virus types, which are encoded by the late HPV 
gene L1 (Villa et al., 2005; Brown and Gaston, 2006). 
 
However, although the two vaccines have been found to be highly effective in the 
prevention against the infections of the particular HPV strains the vaccines were 
designed to protect, they are still far from being an effective measure against cervical 
cancers. Firstly, the vaccines are only effective against infection relating to the HPV 
types included in the vaccine but have partial or no efficacy against other HPV types. 
Since HPV16 and 18 only account for approximately 75 % of cervical cancers, the 
vaccines do not have the ability to protect against all cervical cancers. Secondly, due 
to the high cost of the vaccines at the moment, they cannot be administered to the 
women in developing countries where more than 80 % of cervical cancer deaths 
occurred. Lastly, seeing that the vaccines can only prevent the infection of HPV and 
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lack the therapeutic effect on HPV infection, they are not beneficial to the high 
prevalence of women infected by HPV. Moreover, slow process of carcinogenesis of 
the HPV infection coupled with the fact that the existing vaccines have no effect in 
preventing the ongoing neoplastic processes, it has been estimated that it would take 
approximately 20 to 30 years of the implementation of mass vaccinations to reduce 
the world-wide incidence of cervical cancer or related deaths (Lambert & Brake, 2005; 
Elbasha et al., 2007). Therefore, the need for HPV screening tool and cervical cancer 
therapeutics cannot be diminished. 
 
Current treatment for cervical cancer in advanced stage includes chemotherapy 
whereby platinum-based derivatives such as cisplatin, combined with radiotherapy 
using gamma irradiation. These chemoradiotherapy targets the rapidly dividing cancer 
cells by inducing DNA damage, thus triggering the up-regulation of p53 and the p53-
dependent apoptotic cascades. Nevertheless, normal cells in patients undergoing such 
therapies are also affected, as the drugs do not discriminate between tumours and non-
tumours cells, leading to unwanted side effects. Besides that, there are patients who 
develop resistance to cisplatin, limiting its effect (Mellish et al, 1993; Britten et al, 
2000; Bai et al, 2006). Hence a more specific target for cervical cancer will no doubt 
have tremendous therapeutic potential in cervical cancer treatment. 
 
Recently the use of interference RNA (RNAi) or small interfering RNA (siRNA) has 
emerged as a direct treatment for many types of cancer (Davis et al, 2010). The 
precise targeting of specific genes by RNAi stands out as one of the most favourable 
cancer therapies in the near future. Due to the prominent roles of oncogenic proteins 
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E6 and E7 in cervical cancer tumorigenesis, much effort has been made to explore the 
therapeutic potentials of direct suppression of E6 and E7 expression through the use 
of siRNAs or over-expression of E2 proteins in vitro and in vivo (Jiang & Milner, 
2002; Jonson et al, 2008; Yamato et al, 2008). However, owing to the highly specific 
nature of the siRNAs, specific subtype of the HPV needed to be determined before 
corresponding E6 or E7 siRNAs can be employed. Moreover, HPV infections can 
consist of multiple subtypes at different period of time, which will further complicate 
the choice of siRNAs to use (Sasagawa et al, 2001; Bello et al, 2009; Schmitt et al, 
2010; Andersson et al, 2012). 
 
Due to the ability of MLL5β-siRNA to down-regulate both E6 and E7 expression, it 
has synergistically enhanced anti-cancer effect compared to E6 or E7-siRNA alone, as 
shown in both in vitro and in vivo assays (Figure 20 and 21). This could be a result of 
MLL5β-siRNA treated cells have both apoptosis and senescence pathway activated 
(Figure 19). Besides that, since MLL5β activates both E6/E7 expression in HPV16 
and HPV18, it can be employed to down-regulate both HPV16/18-positive cells, 
unlike the E6 and E7-siRNA which is subtype-specific. Moreover, comparing to 
cisplatin, MLL5β-siRNA is highly specific to HPV16/18-positive cancer cells since it 
only targets MLL5β that was found to be expressed exclusively in these cancer cells. 
Therefore, this highly specific nature of MLL5β-siRNA significantly lowers the 
adverse side effects brought by less specific cisplatin, as shown in Figure 23 where 
cisplatin as low as 5 μM caused a higher cytotoxicity effect to normal WI-38 cells 
compared to MLL5β-siRNA. Besides that, we also established that cisplatin exerts its 
anti-cancer effect through mechanism that involves MLL5β (Figure 25). Therefore, by 
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targeting at MLL5β directly, we are able to achieve comparable or better anti-cancer 
effect as cisplatin without the undesirable side effects. 
 
The successful detection of MLL5β in primary cervical tumors implies the importance 
of this isoform physiologically. It will be interesting to explore the association of 
MLL5 expression with various stages of cervical carcinoma and the result may lead 
to the discovery of a novel biomarker for cervical cancer diagnosis. Furthermore, 
HPV infections are known to associate with other cancers such as head and neck 
cancer (Paz et al, 1997; Syrjanen, 2005; Schlecht et al, 2007).  It will be intriguing to 
explore whether MLL5β plays a similar role in activating E6/E7 transcription in these 
HPV-related cancers. We are also interested in investigating the role of MLL5β in 
cancers induced by other high-risk HPV subtype such as HPV31 and HPV45 so that 
MLL5β-siRNA could potentially be a universal drug for all HPV-related cancers, 
provided if we can establish that MLL5β plays a similar role in all HPV subtypes. 
Another strategy to apply the discovery of MLL5β into the treatment of HPV-related 
cancers is the usage of a small molecule drugs to disrupt the interaction between 
MLL5β and AP-1, thereby achieving the effect of E6/E7 inactivation. One example 
would be arsenic trioxide that has been found to disrupt LCR activity through AP-1 in 
HeLa cells (Um et al, 2002). 
 
Due to the small number of human primary cervical carcinoma samples tested (n=8) 
(Figure 8), no significant conclusion can be drawn on whether MLL5β expression is 
exclusive in HPV16/18-related cervical carcinomas. Besides that, due to the lack of 
cervical cancer cell lines associated with other HPV subtype besides HPV16 and 18, 
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no in vitro studies can be done to investigate whether MLL5β can be detected in other 
HPV subtypes-infected cells. However, some preliminary experiments have been 
carried out with human keratinocytes infected with full HPV16/18 genome and C33A 
cells infected with HPV11 genome to detect MLL5β expression in these infected cells 
(Chow et al, 2010; Wang et al, 2011). Semi-quantitative RT-PCR results have shown 
a 60-fold increase of MLL5β mRNA in these infected cells compared to HPV-
negative cell lines (p<0.001) but relatively low compared to over 5000-fold increase 
detected in HeLa, CaSki or SiHa cells. It will be interesting to monitor the changes in 
MLL5β expression in these infected cells over prolonged period to investigate 
whether MLL5β induction is related to the prolonged infection of HPV. More work 
needs to be done to fully understand the mechanism behind MLL5β induction upon 
HPV infection but these preliminary results seem to indicate that MLL5β is induced 
regardless of infection by high risk or low risk-HPV and the regulation of the MLL5β 
expression is essential to the tumorigenesis of HPV-related cervical cancers. 
 
Besides that, to assess the potential of MLL5β as a biomarker to detect cervical cancer 
progression, more clinical studies with larger sample size are needed. Collaborative 
projects with hospitals have been initiated to obtain more primary samples for MLL5β 
detection. However, since employing semi-quantitative RT-PCR for MLL5β detection 
involves the extraction of RNA which is easily degradable and relatively time-
consuming, high-throughput detection is not realistic. Therefore, MLL5β profiling by 
immunohistochemistry (IHC) method is a more feasible method (Warford et al, 2004). 
A highly specific monoclonal antibody that can target MLL5β but not full-length 
MLL5 is essential for the IHC profiling of MLL5β. Moreover, the localization of the 
MLL5β can be studied by using the IHC method as well. Nevertheless, due to the 
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only 1 amino acid difference between MLL5β and full-length MLL5, the generation 





In conclusion, we have successfully identified a novel MLL5 isoform (MLL5) which 
plays a role in activating E6/E7 through the formation of a complex with AP-1 and 
binds to the distal region of the HPV-18 LCR. Upon depletion of MLL5β using 
siRNA, E6 and E7 oncoproteins are down-regulated, leading to the restoration of p53 
and hypo-phosphorylated Rb, thereby re-establishing the cell cycle checkpoint 
controls. Due to the simultaneous down-regulation of E6 and E7 transcripts by this 
isoform, we suggested that MLL5β may be a more effective therapeutic target than E6 
or E7 individually. Moreover, our study provides a platform for further investigations 
on the novel mechanism in which isoforms may be derived upon viral infection and 
the possibilities of MLL5β as a biomarker for HPV-induced cervical cancers.  
 
Secondly, we have successfully demonstrated the potential of MLL5β-specific siRNA 
as a novel therapeutic agent for HPV16/18-positive human cervical cancer. MLL5β-
siRNA offers higher specificity, higher efficiency and higher flexibility when 
compare to the conventional treatment of using cisplatin; or the proposed method of 
employing E6 and E7-specific siRNA. Our study highlighted the MLL5β-siRNA can 
induced both apoptosis and senescence pathways in HPV16/18-positive cervical 
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